[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 865
1. de Fost M, Vom Dahl S, Weverling GJ, Brill N, Brett S, Häussinger D, Hollak CE: Increased incidence of cancer in adult Gaucher disease in Western Europe. Blood Cells Mol Dis; 2006 Jan-Feb;36(1):53-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased incidence of cancer in adult Gaucher disease in Western Europe.
  • The adult form of Gaucher disease (type I GD) is associated with a high prevalence of hypergammaglobulinemia and monoclonal gammopathy of undetermined significance (MGUS).
  • A total of 14 GD patients of non-Ashkenazi-Jewish descent were identified of whom 5 had a hematologic malignancy.
  • These strongly increased risks on developing cancer suggest that measures for early detection and prevention of hematological and hepatic malignancies in patients with Gaucher type I disease are mandatory.
  • [MeSH-major] Carcinoma, Hepatocellular / mortality. Gaucher Disease / mortality. Multiple Myeloma / mortality


2. Créange A, Chater A, Brouet JC, Jaccard A, Rahmouni A, Lefaucheur JP, Santin A: A case of POEMS syndrome treated by autologous hematopoietic stem-cell transplantation. Nat Clin Pract Neurol; 2008 Dec;4(12):686-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of POEMS syndrome treated by autologous hematopoietic stem-cell transplantation.
  • DIAGNOSIS: Neuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome.
  • MANAGEMENT: High-dose chemotherapy and autologous hematopoietic stem-cell transplantation.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. POEMS Syndrome / therapy

  • Genetic Alliance. consumer health - POEMS syndrome.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19043425.001).
  • [ISSN] 1745-8358
  • [Journal-full-title] Nature clinical practice. Neurology
  • [ISO-abbreviation] Nat Clin Pract Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


3. Gniadecki R, Lukowsky A: Monoclonal T-cell dyscrasia of undetermined significance associated with recalcitrant erythroderma. Arch Dermatol; 2005 Mar;141(3):361-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monoclonal T-cell dyscrasia of undetermined significance associated with recalcitrant erythroderma.
  • BACKGROUND: Erythroderma is a diffuse, inflammatory skin reaction that, in rare instances, is associated with hematologic malignancies such as cutaneous T-cell lymphoma (erythrodermic mycosis fungoides) or T-cell leukemia (Sezary syndrome or adult T-cell leukemia/lymphoma).
  • OBSERVATIONS: We screened 30 patients with erythroderma (20 patients with erythroderma of known etiology and 10 patients with idiopathic erythroderma) for the presence of circulating monoclonal T-lymphocyte populations using T-cell receptor (TCR)-gamma gene-specific polymerase chain reaction and automated capillary DNA electrophoresis.
  • In 5 patients with idiopathic erythroderma we detected T-cell clones in peripheral blood (in 1 case, associated with the presence of the same clone in the skin) and a 2-fold increase in the proportion of CD3+ CD4+ CD7- CD26- cells.
  • Cell depletion studies indicated that the monoclonal T cells were present within the CD4+ CD7- cell population.
  • CONCLUSIONS: A proportion of patients with chronic erythroderma present with the monoclonal expansion of CD4+ CD7- CD26- lymphocytes in their blood.
  • This condition represents a probably benign T-cell dyscrasia, or one of very low malignancy.
  • Alongside monoclonal gammapathy of undetermined significance (MGUS) and monoclonal (B-cell) lymphocytosis of undetermined significance (MLUS), we propose using monoclonal T-cell dyscrasia of undetermined significance (MTUS) to underline a conceptual similarity between this disorder and the more common types of lymphocytic dyscrasia.
  • [MeSH-major] Antigens, CD / immunology. Cell Transformation, Neoplastic / pathology. Dermatitis, Exfoliative / pathology. Lymphoma, T-Cell, Cutaneous / pathology. Precancerous Conditions / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Case-Control Studies. Cohort Studies. Female. Humans. Immunophenotyping. Lymphocyte Activation. Male. Middle Aged. Prognosis. Receptors, Antigen, T-Cell / analysis. Receptors, Antigen, T-Cell / immunology. Risk Assessment

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arch Dermatol. 2006 Mar;142(3):393-4 [16549723.001]
  • (PMID = 15781677.001).
  • [ISSN] 0003-987X
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Receptors, Antigen, T-Cell
  •  go-up   go-down


Advertisement
4. Palladini G, Russo P, Bosoni T, Verga L, Sarais G, Lavatelli F, Nuvolone M, Obici L, Casarini S, Donadei S, Albertini R, Righetti G, Marini M, Graziani MS, Melzi D'Eril GV, Moratti R, Merlini G: Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine. Clin Chem; 2009 Mar;55(3):499-504
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The diagnosis of systemic immunoglobulin light-chain (AL) amyloidosis requires demonstration of amyloid deposits in a tissue biopsy and amyloidogenic monoclonal light chains.
  • We characterized the monoclonal light chain by using IFE and HR-IFE in serum and urine and the FLC kappa/lambda ratio in serum.
  • RESULTS: The HR-IFE of serum and urine identified the amyloidogenic light chain in all 115 patients with a monoclonal gammopathy.
  • Six patients with a biclonal gammopathy were omitted from the statistical analysis.
  • CONCLUSIONS: The identification of amyloidogenic light chains cannot rely on a single test and requires the combination of a commercially available FLC assay with immunofixation of both serum and urine.

  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • Archivio Istituzionale della Ricerca Unimi. Full text from AIR - Univ. Milan .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19131635.001).
  • [ISSN] 1530-8561
  • [Journal-full-title] Clinical chemistry
  • [ISO-abbreviation] Clin. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Immunoglobulin Light Chains
  •  go-up   go-down


5. Olteanu H, Wang HY, Chen W, McKenna RW, Karandikar NJ: Immunophenotypic studies of monoclonal gammopathy of undetermined significance. BMC Clin Pathol; 2008;8:13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunophenotypic studies of monoclonal gammopathy of undetermined significance.
  • BACKGROUND: Monoclonal gammopathy of undetermined significance (MGUS) is a common plasma cell dyscrasia, comprising the most indolent form of monoclonal gammopathy.
  • However, approximately 25% of MGUS cases ultimately progress to plasma cell myeloma (PCM) or related diseases.
  • In this study, we examined the immunophenotypic differences of plasma cells in MGUS and PCM.
  • METHODS: Bone marrow specimens from 32 MGUS patients and 32 PCM patients were analyzed by 4-color flow cytometry, using cluster analysis of ungated data, for the expression of several markers, including CD10, CD19, CD20, CD38, CD45, CD56 and surface and intracellular immunoglobulin light chains.
  • RESULTS: All MGUS patients had two subpopulations of plasma cells, one with a "normal" phenotype [CD19(+), CD56(-), CD38(bright +)] and one with an aberrant phenotype [either CD19(-)/CD56(+) or CD19(-)/CD56(-)].
  • The normal subpopulation ranged from 4.4 to 86% (mean 27%) of total plasma cells.
  • Only 20 of 32 PCM cases showed an identifiable normal subpopulation at significantly lower frequency [range 0-32%, mean 3.3%, p << 0.001].
  • The plasma cells in PCM were significantly less likely to express CD19 [1/32 (3.1%) vs. 13/29 (45%), p << 0.001] and more likely to express surface immunoglobulin [21/32 (66%) vs. 3/28 (11%), p << 0.001], compared to MGUS.
  • Those expressing CD19 did so at a significantly lower level than in MGUS, with no overlap in mean fluorescence intensities [174 +/- 25 vs. 430 +/- 34, p << 0.001].
  • Two of the six MGUS cases (33%) with >90% CD19(-) plasma cells showed progression of disease, whereas none of the cases with >10% CD19(+) plasma cells evolved to PCM.
  • CONCLUSION: MGUS cases with potential for disease progression appeared to lack CD19 expression on >90% of their plasma cells, displaying an immunophenotypic profile similar to PCM plasma cells.
  • A higher relative proportion of CD19(+) plasma cells in MGUS may be associated with a lower potential for disease progression.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2007 Oct 1;110(7):2586-92 [17576818.001]
  • [Cites] Blood Cells Mol Dis. 2000 Dec;26(6):634-45 [11358356.001]
  • [Cites] Am J Clin Pathol. 2007 Feb;127(2):176-81 [17210522.001]
  • [Cites] Blood. 2006 Dec 15;108(13):4194-7 [16946299.001]
  • [Cites] Am J Clin Pathol. 2006 Dec;126(6):908-15 [17153775.001]
  • [Cites] Br J Haematol. 2006 Sep;134(6):573-89 [16938117.001]
  • [Cites] N Engl J Med. 2006 Mar 30;354(13):1362-9 [16571879.001]
  • [Cites] Int J Hematol. 2006 Jan;83(1):39-43 [16443550.001]
  • [Cites] Haematologica. 2005 Oct;90(10):1365-72 [16219573.001]
  • [Cites] Leuk Res. 2005 Nov;29(11):1361-4 [15878199.001]
  • [Cites] Haematologica. 2008 Mar;93(3):431-8 [18268286.001]
  • [Cites] Blood. 2005 Aug 1;106(3):812-7 [15855274.001]
  • [Cites] Leukemia. 2005 Mar;19(3):449-55 [15674420.001]
  • [Cites] Pathol Biol (Paris). 1999 Feb;47(2):89-97 [10192875.001]
  • [Cites] Pathol Biol (Paris). 1999 Feb;47(2):119-27 [10192879.001]
  • [Cites] Am J Pathol. 1998 Jun;152(6):1655-65 [9626070.001]
  • [Cites] Blood. 1998 Jan 1;91(1):3-21 [9414264.001]
  • [Cites] Br J Haematol. 1997 Apr;97(1):46-55 [9136941.001]
  • [Cites] Br J Haematol. 1996 Jul;94(1):76-81 [8757512.001]
  • [Cites] Blood. 1993 May 15;81(10):2658-63 [8490175.001]
  • [Cites] Am J Clin Pathol. 2004 Apr;121(4):482-8 [15080299.001]
  • [Cites] Blood. 2003 Dec 15;102(13):4504-11 [12947006.001]
  • [Cites] Immunol Rev. 2003 Aug;194:105-11 [12846811.001]
  • [Cites] Blood. 2003 Jul 1;102(1):36-42 [12560234.001]
  • [Cites] Br J Haematol. 2003 Jun;121(5):749-57 [12780789.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3095-100 [12384404.001]
  • [Cites] Hematol Oncol. 2002 Jun;20(2):75-85 [12111870.001]
  • [Cites] Nat Rev Cancer. 2002 Mar;2(3):175-87 [11990854.001]
  • [Cites] Am J Pathol. 2002 Apr;160(4):1293-9 [11943714.001]
  • [Cites] N Engl J Med. 2002 Feb 21;346(8):564-9 [11856795.001]
  • [Cites] Haematologica. 2001 Aug;86(8):837-43 [11522540.001]
  • [Cites] Blood Rev. 2007 Sep;21(5):255-65 [17367905.001]
  • (PMID = 19040735.001).
  • [ISSN] 1472-6890
  • [Journal-full-title] BMC clinical pathology
  • [ISO-abbreviation] BMC Clin Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2606678
  •  go-up   go-down


6. Wang XW: [Pathogenesis and management of hemorrhage and thrombosis in plasma cell dyscrasias]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Jun;18(3):809-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pathogenesis and management of hemorrhage and thrombosis in plasma cell dyscrasias].
  • Unexpectedly high rates of venous thromboembolic events (VTE) induced by highly effective immune modulating drugs thalidomide and lenalidomide for treatment of multiple myeloma have focused attention on the incidence and underlying pathophysiology of VTE in patients with plasma cell dyscrasias, and on thromboprophylaxis approaches.
  • While bleeding complications are relatively uncommon in the patients with lymphoproliferative disorders, acquired von Willebrand syndrome, typically occurring in the patients with monoclonal gammopathy of unknown significance, and acquired coagulopathies associated with primary amyloidosis can present with haemorrhagic complications and both are challenges to the management.
  • This review highlights these important haemostasis-related complications of plasma cell dyscrasias and provides an overview of other uncommon bleeding and thrombotic events that can affect diagnosis and therapeutic management of clonal plasma cell disorders.

  • Genetic Alliance. consumer health - Thrombosis.
  • MedlinePlus Health Information. consumer health - Bleeding.
  • MedlinePlus Health Information. consumer health - Blood Clots.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20561456.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] China
  •  go-up   go-down


7. Garcia T, Dafer R, Hocker S, Schneck M, Barton K, Biller J: Recurrent strokes in two patients with POEMS syndrome and Castleman's disease. J Stroke Cerebrovasc Dis; 2007 Nov-Dec;16(6):278-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent strokes in two patients with POEMS syndrome and Castleman's disease.
  • POEMS syndrome is a disorder characterized by polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes.
  • Castleman's disease is a rare lymphoproliferative disorder that can be present in patients with POEMS syndrome.
  • However, only 3 patients have ever been described with POEMS syndrome, Castleman's disease, and stroke.
  • We suspect that the strokes are a result of a possible intracranial vasculopathic process.
  • [MeSH-major] Brain Ischemia / complications. Giant Lymph Node Hyperplasia / diagnosis. POEMS Syndrome / diagnosis. Stroke / etiology

  • Genetic Alliance. consumer health - Castleman's Disease.
  • Genetic Alliance. consumer health - POEMS syndrome.
  • MedlinePlus Health Information. consumer health - Ischemic Stroke.
  • MedlinePlus Health Information. consumer health - Stroke.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18035247.001).
  • [ISSN] 1532-8511
  • [Journal-full-title] Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association
  • [ISO-abbreviation] J Stroke Cerebrovasc Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Bochtler T, Hegenbart U, Heiss C, Benner A, Cremer F, Volkmann M, Ludwig J, Perz JB, Ho AD, Goldschmidt H, Schonland SO: Evaluation of the serum-free light chain test in untreated patients with AL amyloidosis. Haematologica; 2008 Mar;93(3):459-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The FLC test detected the monoclonal gammopathy in 87% compared with 92% for immunofixation of serum and urine in combination.
  • Higher FLC levels were associated with higher bone marrow plasmocytosis, poorer Karnofsky index and heart involvement, and therefore reflected disease severity.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bone Marrow / pathology. Female. Humans. Karnofsky Performance Status. Kidney / pathology. Kidney Failure, Chronic / blood. Kidney Failure, Chronic / etiology. Kidney Failure, Chronic / pathology. Kidney Failure, Chronic / urine. Male. Middle Aged. Myocardium / pathology. Nephelometry and Turbidimetry. Plasma Cells / pathology. Severity of Illness Index

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18287137.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Amyloid; 0 / Immunoglobulin Light Chains
  •  go-up   go-down


9. Rey JB, Luria RB: Treatment of scleromyxedema and the dermatoneuro syndrome with intravenous immunoglobulin. J Am Acad Dermatol; 2009 Jun;60(6):1037-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Scleromyxedema is a rare disease characterized by extensive mucin deposition with fibrosis, and is associated with a monoclonal gammopathy.
  • Currently there is no consensus on optimal treatment of this potentially fatal disease because of the lack of randomized controlled trials and limited number of case reports.

  • Genetic Alliance. consumer health - Scleromyxedema.
  • MedlinePlus Health Information. consumer health - Neurologic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19249127.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulins, Intravenous
  •  go-up   go-down


10. Landgren O, Gridley G, Turesson I, Caporaso NE, Goldin LR, Baris D, Fears TR, Hoover RN, Linet MS: Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood; 2006 Feb 1;107(3):904-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States.
  • A few small studies have reported a higher prevalence of monoclonal gammopathy of undetermined significance (MGUS) in African Americans versus whites.
  • Etiologic factors for MGUS and determinants for transformation of MGUS to MM are unknown.
  • We quantified the prevalence of MGUS and subsequent risk of MM among 4 million African American and white male veterans admitted to Veterans Affairs (VA) hospitals.
  • The age-adjusted prevalence ratio of MGUS in African Americans compared with whites was 3.0 (2.7-3.3 95% confidence interval).
  • Among 2046 MGUS cases, the estimated cumulative risk of MM during the first 10 years of follow-up was similar (P = .37) for African Americans (17%) and whites (15%).
  • In the largest study to date, we suggest that the excess risk of MM in African Americans results from an increase in risk of MGUS rather than an increased risk of progression from MGUS to MM.

  • Genetic Alliance. consumer health - Multiple myeloma.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2002 Feb 21;346(8):564-9 [11856795.001]
  • [Cites] Blood. 2004 Aug 1;104(3):607-18 [15090448.001]
  • [Cites] Blood. 2005 Sep 15;106(6):2156-61 [15920009.001]
  • [Cites] J Lab Clin Med. 1990 Dec;116(6):785-9 [2246554.001]
  • [Cites] Am J Med. 1998 May;104(5):439-44 [9626026.001]
  • [Cites] Acta Med Scand. 1966 Feb;179(2):235-47 [4160039.001]
  • (PMID = 16210333.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1895893
  •  go-up   go-down


11. Pittock SJ, Lennon VA: Aquaporin-4 autoantibodies in a paraneoplastic context. Arch Neurol; 2008 May;65(5):629-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • (1) 31 patients (88% female) identified incidentally among 180 000 patients evaluated for paraneoplastic autoantibodies and (2) 141 patients identified through physician-requested serological evaluation for a suspected NMO-spectrum disorder.
  • An NMO-spectrum disorder was diagnosed in 26 patients (93%), of whom 6 had a neoplasm (5 carcinomas [2 breast, 1 lung, 1 thymic, and 1 uterine cervical] and 1 B-cell lymphoma) and 1 had monoclonal gammopathy.
  • Two patients had carcinoma (1 breast and 1 lung) without neurological evidence of an NMO-spectrum disorder.
  • In the second group, neoplasms were recorded in 7 seropositive patients (5.0%) with a clinically diagnosed NMO-spectrum disorder: 3 carcinomas (all breast), 1 thyroid Hürthle cell, 1 carcinoid, 1 pituitary somatotropinoma, and 1 B-cell lymphoma.
  • An eighth patient had monoclonal gammopathy.
  • The clinical utility of this autoantibody as a cancer marker warrants prospective investigation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Arch Neurol. 2008 Oct;65(10):1394
  • (PMID = 18474738.001).
  • [ISSN] 1538-3687
  • [Journal-full-title] Archives of neurology
  • [ISO-abbreviation] Arch. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aquaporin 4; 0 / Autoantibodies; 0 / Biomarkers; 0 / Immunoglobulin G
  •  go-up   go-down


12. Muslimani AA, Spiro TP, Chaudhry AA, Taylor HC, Jaiyesimi I, Daw HA: Venous thromboembolism in patients with monoclonal gammopathy of undetermined significance. Clin Adv Hematol Oncol; 2009 Dec;7(12):827-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Venous thromboembolism in patients with monoclonal gammopathy of undetermined significance.
  • Monoclonal gammopathy of undetermined significance (MGUS) is defined by the presence of a serum M-protein at a concentration of 3 g/dL or less, with less than 10% plasma cells in the bone marrow, and the absence of lytic bone lesions, anemia, hypercalcemia, and renal insufficiency related to the plasma cell proliferative process.
  • The annual risk of MGUS progressing to a symptomatic plasma cell proliferation or other related malignancy is approximately 1%.
  • In this retrospective study of MGUS patients, VTE was seen in 8% (9/112) of patients, a rate that is 22.8-fold higher than that in the general population (P is less than .001).
  • Although many studies have identified VTE as a marker for subsequent malignancy, we did not find a significant difference in the incidence of VTE as a function of the risk factor group.
  • [MeSH-major] Monoclonal Gammopathy of Undetermined Significance / complications. Venous Thromboembolism / epidemiology
  • [MeSH-minor] Disease Progression. Humans. Retrospective Studies. Risk Assessment. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20332755.001).
  • [ISSN] 1543-0790
  • [Journal-full-title] Clinical advances in hematology & oncology : H&O
  • [ISO-abbreviation] Clin Adv Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Decaux O, Ruelland A, Grosbois B: Effect of treatment on biclonal gammopathy associated with Gaucher disease. J Inherit Metab Dis; 2007 Oct;30(5):824
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of treatment on biclonal gammopathy associated with Gaucher disease.
  • The non-random association of Gaucher disease with polyclonal and monoclonal gammopathy has been known since 1950.
  • The effect of treatment on monoclonal gammopathy is not well documented.
  • We report on the long-term evolution of a biclonal gammopathy in a patient with type I Gaucher disease who was treated with splenectomy and enzyme replacement therapy.
  • Immunofixation identified two monoclonal components: IgG kappa and IgA kappa.
  • Our observation and previous reports suggest that enzyme replacement therapy is more effective in polyclonal hypergammaglobulinaemia than in monoclonal gammopathy.
  • [MeSH-major] Gaucher Disease / drug therapy. Glucosylceramidase / therapeutic use. Paraproteinemias / etiology. Splenectomy. gamma-Globulins / metabolism

  • Genetic Alliance. consumer health - BabysFirstTest - Gaucher Disease.
  • Genetic Alliance. consumer health - Gaucher Disease.
  • MedlinePlus Health Information. consumer health - Gaucher Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17879146.001).
  • [ISSN] 1573-2665
  • [Journal-full-title] Journal of inherited metabolic disease
  • [ISO-abbreviation] J. Inherit. Metab. Dis.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Recombinant Proteins; 0 / gamma-Globulins; EC 3.2.1.- / Hexosaminidases; EC 3.2.1.- / chitotriosidase; EC 3.2.1.45 / Glucosylceramidase; EC 3.2.1.45 / imiglucerase
  •  go-up   go-down


14. Ito Y, Nishimura K, Yamanaka K, Hakamada A, Isoda K, Kurokawa I, Mizutani H: Necrobiotic xanthogranuloma with paraproteinemia; an atypical case. J Dtsch Dermatol Ges; 2008 Jan;6(1):40-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Biopsies showed a non-palisading granuloma with numerous multinucleated giant cells showing prominent elastophagocytosis and extensive areas of necrobiosis throughout the entire dermis.
  • Immunohistochemical staining detected the presence of roughly equal numbers of IgG-lambda-and IgG-kappa-staining plasma cells in the dermis.
  • We diagnosed NXG with paraproteinemia with monoclonal gammopathy (IgG-lambda type) of unknown significance.

  • Genetic Alliance. consumer health - Xanthogranuloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17941882.001).
  • [ISSN] 1610-0387
  • [Journal-full-title] Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
  • [ISO-abbreviation] J Dtsch Dermatol Ges
  • [Language] eng; ger
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


15. Pérez-Andrés M, Almeida J, Martín-Ayuso M, Moro MJ, Martín-Nuñez G, Galende J, Borrego D, Rodríguez MJ, Ortega F, Hernandez J, Moreno I, Domínguez M, Mateo G, San Miguel JF, Orfao A, Spanish Network on multiple myeloma (G03/136), Spanish Network of Cancer Research Centers (C03/10): Clonal plasma cells from monoclonal gammopathy of undetermined significance, multiple myeloma and plasma cell leukemia show different expression profiles of molecules involved in the interaction with the immunological bone marrow microenvironment. Leukemia; 2005 Mar;19(3):449-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clonal plasma cells from monoclonal gammopathy of undetermined significance, multiple myeloma and plasma cell leukemia show different expression profiles of molecules involved in the interaction with the immunological bone marrow microenvironment.
  • The immunological bone marrow (BM) microenvironment plays a major role in controlling growth and survival of clonal plasma cells (PC); this might translate into different patterns of expression of molecules involved in immune responses on PC from different types of monoclonal gammopathies (MG).
  • We have studied the expression of a group of nine such molecules on both BMPC and the plasma of 61 newly diagnosed MG patients (30 MG of undetermined significance (MGUS), 27 multiple myeloma (MM) and four plasma cell leukemia (PCL)) and five normal individuals.
  • Clonal PC from all MG displayed significantly increased levels of CD56, CD86 and CD126, and decreased amounts of CD38 (P<0.001).
  • Additionally, HLA-I and beta2-microglobulin were abnormally highly expressed in MGUS, while CD40 expression was decreased in MM and PCL (P<0.05).
  • Interestingly, a progressive increase in the soluble levels of beta2-microglobulin was found from MGUS to MM and PCL patients (P=0.03).
  • Overall, those phenotypic differences are consistent with increased antigen presentation and costimulatory capacities in MGUS, which progressively deteriorate in malignant MG (MM and PCL).
  • [MeSH-major] Antigens, CD / genetics. Bone Marrow / pathology. Leukemia, Plasma Cell / genetics. Multiple Myeloma / genetics. Paraproteinemias / immunology. Plasma Cells / immunology


16. Chim CS, Liang R, Leung MH, Kwong YL: Aberrant gene methylation implicated in the progression of monoclonal gammopathy of undetermined significance to multiple myeloma. J Clin Pathol; 2007 Jan;60(1):104-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant gene methylation implicated in the progression of monoclonal gammopathy of undetermined significance to multiple myeloma.
  • Malignant transformation is a multistep process that may involve dysregulation of oncogenes and tumour suppressor genes, and monoclonal gammopathy of undetermined significance (MGUS) is believed to be a precursor of multiple myeloma.
  • To investigate whether aberrant promoter methylation might be involved in the evolution of MGUS to multiple myeloma, we examined the p16, protein tyrosine phosphatase, non-receptor type 6 (SHP1), death-associated protein (DAP) kinase, E-cadherin and oestrogen receptor genes, most being tumour suppressor genes, by methylation-specific polymerase chain reaction.
  • In 32 cases of multiple myeloma and 19 cases of MGUS, significantly more frequent methylation of p16 (p = 0.001), SHP1 (p< or =0.001) and E-cadherin (p< or =0.001) genes was found in multiple myeloma than in MGUS.
  • Methylation of DAP kinase and oestrogen receptor genes was comparable in multiple myeloma and MGUS.
  • In conclusion, methylation of p16, SHP1 and E-cadherin genes might be involved in the progression of MGUS to multiple myeloma.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. DNA, Neoplasm / genetics. Disease Progression. Female. Genes, Tumor Suppressor. Humans. Male. Middle Aged. Multiple Myeloma / genetics. Neoplasm Proteins / genetics. Polymerase Chain Reaction / methods. Promoter Regions, Genetic / genetics


17. Hirano T, Hoshino Y: Detection of changes in the nuclear phase and evaluation of male germ units by flow cytometry during in vitro pollen tube growth in Alstroemeria aurea. J Plant Res; 2009 Mar;122(2):225-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sperm cell formation occurred at 6-9 h after culture, indicating that the first change was due to the division of the generative cells into sperm cells.
  • After sperm cell formation, the number of vegetative nucleus associations with sperm cells showed a tendency to increase.
  • When sperm cells, vegetative nuclei, and partial MGUs were collected separately from pollen tubes cultured for 18 h and analyzed using a flow cytometer, the sperm cells and vegetative nuclei contained 1C DNA, while the DNA content of partial MGUs was counted as 2C.
  • Therefore, the second change in the nuclear phase, which results in an increase in 2C nuclei, is possibly related to the formation of MGUs.
  • [MeSH-major] Alstroemeria / genetics. Cell Nucleus / metabolism. Flow Cytometry / methods. Pollen / cytology. Pollen / metabolism. Pollen Tube / growth & development
  • [MeSH-minor] Cell Differentiation. DNA, Plant / chemistry. Genes, Plant

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1985 Sep;82(18):6129-32 [16593605.001]
  • [Cites] Dev Biol. 1973 Jul;33(1):130-7 [4789596.001]
  • [Cites] Development. 1999 Feb;126(5):1065-75 [9927606.001]
  • [Cites] Ann Bot. 2006 Jun;97(6):1139-44 [16621859.001]
  • [Cites] Plant Cell Rep. 2004 Oct;23(4):196-202 [15480680.001]
  • [Cites] Plant J. 2003 Mar;33(6):1051-62 [12631329.001]
  • [Cites] Plant Cell Rep. 2006 Nov;25(11):1138-42 [16786313.001]
  • [Cites] Ann Bot. 2005 Jan;95(1):99-110 [15596459.001]
  • [Cites] Plant Physiol. 1992 May;99(1):54-9 [16668883.001]
  • [Cites] Plant Cell. 1993 Jul;5(7):739-746 [12271084.001]
  • [Cites] Plant Physiol. 1988 Jul;87(3):647-50 [16666200.001]
  • [Cites] Plant Cell. 1998 Apr;10(4):511-24 [9548979.001]
  • [Cites] Plant J. 2002 Oct;32(2):221-31 [12383087.001]
  • [Cites] Planta. 2007 Aug;226(3):581-9 [17361458.001]
  • (PMID = 19151916.001).
  • [ISSN] 1618-0860
  • [Journal-full-title] Journal of plant research
  • [ISO-abbreviation] J. Plant Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / DNA, Plant
  •  go-up   go-down


18. Kaiser M, Mieth M, Liebisch P, Oberländer R, Rademacher J, Jakob C, Kleeberg L, Fleissner C, Braendle E, Peters M, Stover D, Sezer O, Heider U: Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma. Eur J Haematol; 2008 Jun;80(6):490-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma.
  • OBJECTIVES: Lytic bone disease is a hallmark of multiple myeloma (MM) and is caused by osteoclast activation and osteoblast inhibition.
  • METHODS: DKK-1 serum levels were quantified in 184 untreated MM patients and 33 monoclonal gammopathy of undetermined significance (MGUS) patients by ELISA, using a monoclonal anti-DKK-1 antibody.
  • RESULTS: Serum DKK-1 was elevated in MM as compared with MGUS (mean 11 963 pg/mL vs. 1993 pg/mL; P < 0.05).
  • Importantly, myeloma patients without lytic lesions in conventional radiography had significantly lower DKK-1 levels than patients with lytic bone disease (mean 3114 pg/mL vs. 17 915 pg/mL; P = 0.003).
  • CONCLUSION: Using a large series of myeloma patients, we could show for the first time a correlation between DKK-1 serum concentration and the amount of lytic bone disease, indicating that DKK-1 is an important factor for the extent of bone disease and supporting the hypothesis of DKK-1 as a therapeutic target in myeloma bone disease.

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Bone Diseases.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18331598.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / DKK1 protein, human; 0 / Intercellular Signaling Peptides and Proteins
  •  go-up   go-down


19. Decaux O, Rodon P, Ruelland A, Estepa L, Leblay R, Grosbois B: [Epidemiology of monoclonal gammopathy in a general hospital and a university internal medicine department]. Rev Med Interne; 2007 Oct;28(10):670-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epidemiology of monoclonal gammopathy in a general hospital and a university internal medicine department].
  • [Transliterated title] Epidémiologie descriptive des gammapathies monoclonales. Expérience d'un centre hospitalier général et d'un service de médecine interne de centre hospitalier et universitaire.
  • PURPOSE: Monoclonal gammopathy are common in the general population.
  • We describe biological features and etiology of monoclonal gammopathy diagnosed during more than a ten year period in the Internal Medicine Department of Rennes University Hospital and in all the medical departments of General Hospital of Blois.
  • RESULTS: Internal Medicine Department of Rennes University Hospital: 1051 monoclonal gammapathies were identified: 514 men and 537 women.
  • Isotypes repartition was: IgG 42.8% (450 cases), IgM 31.9% (335), IgA 8.9% (94) biclonal gammopathy 9.8% (103).
  • Sixty-nine monoclonal light chains (6.6%) were identified.
  • Median concentration of monoclonal protein was 14 g/l (1.8-104.4).
  • All department of General Hospital of Blois: 1282 monoclonal gammapathies were identified: 700 men and 582 women.
  • Thirty-four monoclonal light chains (2.7%) were identified.
  • Median concentration of monoclonal protein was 5.6 g/l (0.5-96.6).
  • Most frequent diagnosis were: monoclonal gammopathy of undetermined significance or MGUS (77.6% in Blois and 64.1% in Rennes), multiple myeloma (11.9% and 12.7%), Waldenström's macroglobulinemia (4.4% and 8.7%).
  • CONCLUSION: Monoclonal gammopathy are common in clinical practice.
  • MGUS account for more than 60% of monoclonal gammopathy.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17566610.001).
  • [ISSN] 0248-8663
  • [Journal-full-title] La Revue de medecine interne
  • [ISO-abbreviation] Rev Med Interne
  • [Language] FRE
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Immunoglobulin A; 0 / Immunoglobulin G; 0 / Immunoglobulin Isotypes; 0 / Immunoglobulin Light Chains; 0 / Immunoglobulin M
  •  go-up   go-down


20. Wood AJ, Wagner MV, Abbott JJ, Gibson LE: Necrobiotic xanthogranuloma: a review of 17 cases with emphasis on clinical and pathologic correlation. Arch Dermatol; 2009 Mar;145(3):279-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To identify correlations between clinical presentation, specific histopathologic findings, and subsequent disease course in patients with necrobiotic xanthogranuloma (NXG).
  • PATIENTS: Seventeen patients with a diagnosis of NXG established between January 1, 1994, and December 31, 2007.
  • MAIN OUTCOME MEASURES: Description and distribution of clinical lesions, presence of monoclonal gammopathy, multiple myeloma, and correlation with microscopic patterns of skin lesions.
  • Twelve patients (71%) had a monoclonal gammopathy; of these, 3 (18%) had multiple myeloma.
  • Histopathologic examination of 12 patients showed findings consistent with NXG, including a bandlike pattern of necrobiotic granulomatous inflammation, atypical giant cells, cholesterol clefts, and plasma cells.
  • Although most patients had a serum monoclonal gammopathy, staining with antibodies to CD3, CD20, kappa light chains, and lambda light chains showed polytypic lymphocytes and plasma cells in all cases.
  • However, the skin lesions in NXG represent reactive inflammation and are not associated with the presence of monoclonal plasma cells or multiple myeloma.

  • Genetic Alliance. consumer health - Xanthogranuloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19289757.001).
  • [ISSN] 1538-3652
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Heider U, Kaiser M, Mieth M, Lamottke B, Rademacher J, Jakob C, Braendle E, Stover D, Sezer O: Serum concentrations of DKK-1 decrease in patients with multiple myeloma responding to anti-myeloma treatment. Eur J Haematol; 2009 Jan;82(1):31-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, the effect of different treatment regimens for MM on serum DKK-1 was evaluated and correlated with the response to treatment in 101 myeloma patients receiving bortezomib, thalidomide, lenalidomide, adriamycin and dexamethasone (AD) or high-dose chemotherapy (HDCT) followed by autologous stem cell transplantation (ASCT).
  • At baseline, myeloma patients had increased serum DKK-1 as compared with patients with MGUS (mean 3786 pg/mL vs. 1993 pg/mL).
  • Thalidomide led to a non-significant decrease in DKK-1 (1705 pg/mL vs. 1269 pg/mL, P = 0.081).
  • Within all groups, a significant decrease of DKK-1 was only seen in responders (i.e. patients achieving complete remission or partial remission), but not in non-responders.

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19067746.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DKK1 protein, human; 0 / Intercellular Signaling Peptides and Proteins
  •  go-up   go-down


22. Fain O: [Monoclonal gammopathies]. Rev Prat; 2006 Jan 15;56(1):40-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Monoclonal gammopathies].
  • [Transliterated title] Immunoglobulines monoclonales pathogènes.
  • Monoclonal gammopathies can induce clinical or biological symptoms, independent of any associated hemopathy.
  • Peripheral neuropathies associated with monoclonal gammopathy are chronic, distal, symmetrical and progressive, in two thirds of the cases the monoclonal component reacts with a neuronal antigen principally myelin associated glycoprotein.
  • POEMS syndrome is characterized by: polyneuropathy, organomegaly, endocrine disorder, monoclonal component, and skin diseases.
  • Other manifestations are described: angioneurotic oedema, acquired Willebrand disease, systemic capillary leak syndrome, Fanconi syndrome.
  • Treatment of the gammopathy can control associated affections.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16548248.001).
  • [ISSN] 0035-2640
  • [Journal-full-title] La Revue du praticien
  • [ISO-abbreviation] Rev Prat
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 34
  •  go-up   go-down


23. Stankowski-Drengler T, Gertz MA, Katzmann JA, Lacy MQ, Kumar S, Leung N, Hayman SR, Buadi F, Kyle RA, Rajkumar SV, Dispenzieri A: Serum immunoglobulin free light chain measurements and heavy chain isotype usage provide insight into disease biology in patients with POEMS syndrome. Am J Hematol; 2010 Jun;85(6):431-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum immunoglobulin free light chain measurements and heavy chain isotype usage provide insight into disease biology in patients with POEMS syndrome.
  • POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, skin changes) syndrome is a rare paraneoplastic syndrome in which nearly all patients have a monoclonal lambda restricted plasma cell disorder.
  • Cystatin C levels were measured to discern whether subclinical renal insufficiency could account for FLC elevations in the presence of a normal FLC ratio.
  • The rise in serum FLC of POEMS patients appeared to be multifactorial-both a function of subclinical renal insufficiency and polyclonal activation of medullary and extramedullary plasma cells.
  • In summary, serum immunoglobulin profiles are unique in POEMS syndrome as compared with other plasma cell disorders.

  • Genetic Alliance. consumer health - POEMS syndrome.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Wiley-Liss, Inc.
  • [Cites] Clin Chem. 2001 Apr;47(4):673-80 [11274017.001]
  • [Cites] Blood. 2001 May 1;97(9):2900-2 [11313287.001]
  • [Cites] Clin Chem. 2002 Sep;48(9):1437-44 [12194920.001]
  • [Cites] Am J Clin Pathol. 2003 Feb;119(2):274-8 [12579999.001]
  • [Cites] Br J Haematol. 2004 Nov;127(3):308-10 [15491291.001]
  • [Cites] Crit Rev Clin Lab Sci. 2004;41(5-6):467-550 [15603510.001]
  • [Cites] Am J Clin Pathol. 2009 Feb;131(2):166-71 [19141376.001]
  • [Cites] Ann Rheum Dis. 2007 Jan;66(1):23-7 [16569685.001]
  • [Cites] Blood Rev. 2007 Nov;21(6):285-99 [17850941.001]
  • [Cites] Blood. 2008 Jan 15;111(2):785-9 [17942755.001]
  • [Cites] Leuk Lymphoma. 2008 Jun;49(6):1104-7 [18452095.001]
  • [Cites] Clin J Am Soc Nephrol. 2008 Nov;3(6):1684-90 [18945993.001]
  • [Cites] Blood. 2006 Sep 15;108(6):1979-83 [16741249.001]
  • (PMID = 20513121.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA125614-04; United States / NCI NIH HHS / CA / R01 CA125614-04; United States / NCI NIH HHS / CA / P01 CA062242; United States / NCI NIH HHS / CA / R01 CA125614; United States / NCI NIH HHS / CA / CA62242
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CST3 protein, human; 0 / Cystatin C; 0 / Immunoglobulin A; 0 / Immunoglobulin G; 0 / Immunoglobulin Heavy Chains; 0 / Immunoglobulin Light Chains; 0 / Immunoglobulin lambda-Chains
  • [Other-IDs] NLM/ NIHMS213530; NLM/ PMC2902776
  •  go-up   go-down


24. Manoni F, Fornasiero L, Ercolin M, Tinello A, Ferrian M, Valverde S, Gessoni G: Laboratory diagnosis of renal failure: urine conductivity and tubular function. Minerva Urol Nefrol; 2009 Mar;61(1):17-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laboratory diagnosis of renal failure: urine conductivity and tubular function.
  • AIM: Conductivity is a measure of a material's ability to conduct an electric current and it works thanks to movable charges.
  • The aim of this study was to evaluate the significance of urine conductivity by using the Sismex UF-100 analyser in correlations with other surrogate parameters of osmolality and renal diuresis, relative density, electrolytes and creatinine concentration.
  • Samples were collected from 70 healthy subjects, 42 diabetics with poor metabolic control and significant glicosuria, 28 patients with monoclonal gammopathy of uncertain significance, with significant proteinuria.

  • MedlinePlus Health Information. consumer health - Urinalysis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19417723.001).
  • [ISSN] 0393-2249
  • [Journal-full-title] Minerva urologica e nefrologica = The Italian journal of urology and nephrology
  • [ISO-abbreviation] Minerva Urol Nefrol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Electrolytes; AYI8EX34EU / Creatinine
  •  go-up   go-down


25. Wu WC, Chen SC, Hsieh JT, Chen J, Chang HC: Penile tuberculosis associated with monoclonal gammopathy of undetermined significance. J Formos Med Assoc; 2006 Sep;105(9):753-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Penile tuberculosis associated with monoclonal gammopathy of undetermined significance.
  • Monoclonal gammopathy of undetermined significance was diagnosed after serum and urine electrophoresis studies, and repeated bone marrow studies.
  • Although rare, the possibility of TB as a cause of genital ulcer should be kept in mind.

  • Genetic Alliance. consumer health - Tuberculosis.
  • MedlinePlus Health Information. consumer health - Penis Disorders.
  • Hazardous Substances Data Bank. RIFAMPIN .
  • Hazardous Substances Data Bank. ISONIAZID .
  • Hazardous Substances Data Bank. ETHAMBUTOL .
  • Hazardous Substances Data Bank. PYRAZINAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16959623.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  • [Chemical-registry-number] 0 / Antitubercular Agents; 2KNI5N06TI / Pyrazinamide; 8G167061QZ / Ethambutol; V83O1VOZ8L / Isoniazid; VJT6J7R4TR / Rifampin
  •  go-up   go-down


26. Quartarone E, Alonci A, Allegra A, Bellomo G, Calabrò L, D'Angelo A, Del Fabro V, Grasso A, Cincotta M, Musolino C: Differential levels of soluble angiopoietin-2 and Tie-2 in patients with haematological malignancies. Eur J Haematol; 2006 Dec;77(6):480-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The system involving angiopoietin-2 (Ang-2) and its receptor, Tie-2, appears to play an important role not only in tumor angiogenesis, but also in the biology of haematological and non-haematological malignancies.
  • Measurements were carried out in 15 patients with chronic myeloid leukaemia (CML), 25 with essential thrombocythemia (ET), 24 with multiple myeloma (MM) and six with monoclonal gammopathy of undetermined significance (MGUS).
  • In patients with CML and MM the levels of sAng-2 were significantly higher (1686.53 +/- 936.41 pg/mL and 1917.82 +/- 1427 pg/mL, respectively) than in controls (n = 15; 996.096 +/- 414.65 pg/mL) (P < 0.01).
  • In patients with MM sAng-2 levels were significantly increased with increasing stage of disease, from stage I to stage III (P < 0.03) and presented a trend of correlation with Beta2-microglobulin levels (r = 0.317) and grade of bone involvement.
  • Furthermore, the levels of sAng-2 determined after 6 months of chemotherapy in CML patients were significantly lower than at diagnosis in the patients who achieved haematological remission.
  • Circulating sTie-2 levels were increased in patients with ET (17.5 +/- 9.2 vs 9 +/- 3.5 ng/mL; P < 0.01) and in those with CML (16.29 +/- 8.7 ng/mL; P < 0.04).
  • [MeSH-minor] Aged. Disease Progression. Female. Humans. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / metabolism. Male. Middle Aged. Multiple Myeloma / genetics. Multiple Myeloma / metabolism. Neovascularization, Pathologic. Paraproteinemias / genetics. Paraproteinemias / metabolism. Thrombocythemia, Essential / genetics. Thrombocythemia, Essential / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16978237.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Angiopoietin-2; EC 2.7.10.1 / Receptor, TIE-2
  •  go-up   go-down


27. Saito N, Konishi K, Ohta S, Kondo T, Kato M, Hashino S, Takeda H, Asaka M, Ooi HK: Plural light chains in a single plasma cell of a monoclonal gammopathy undetermined significance case: an ultrastructural study. Hum Cell; 2007 Feb;20(1):10-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plural light chains in a single plasma cell of a monoclonal gammopathy undetermined significance case: an ultrastructural study.
  • Bone marrow examination showed normal cellular marrow containing 6.3% of plasma cells with no abnormal features.
  • No chromosomal abnormality was observed at all.
  • The patient was diagnosed as having monoclonal gammopathy of undetermined significance.
  • The bone marrow plasma cells possessed free kappa- and lambda-chains in Golgi apparatus, rough endoplasmic reticula and cytoplasmic matrices.
  • Plural light chains were simultaneously produced with the same heavy chain in a plasma cell by immunoelectron microscopy.
  • This is the first report in the world of a monoclonal gammopathy of undetermined significance producing plural light chains with the same heavy chain.
  • [MeSH-major] Immunoglobulin Light Chains / analysis. Monoclonal Gammopathy of Undetermined Significance / immunology. Plasma Cells / immunology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1986 Jan;83(2):295-8 [3079910.001]
  • [Cites] J Rheumatol. 1998 Apr;25(4):813-5 [9558193.001]
  • [Cites] Immunity. 1997 Mar;6(3):303-13 [9075931.001]
  • [Cites] Am J Med. 1987 Jan;82(1):39-45 [3492143.001]
  • [Cites] Blood. 2006 Feb 1;107(3):904-6 [16210333.001]
  • [Cites] Am J Pathol. 1991 Nov;139(5):1053-9 [1719819.001]
  • [Cites] Am J Med. 1981 Dec;71(6):999-1008 [6797297.001]
  • [Cites] Ultrastruct Pathol. 1998 Nov-Dec;22(6):421-9 [9891920.001]
  • [Cites] Blood. 2002 Mar 1;99(5):1745-57 [11861292.001]
  • [Cites] Clin Infect Dis. 1999 Mar;28(3):678-9 [10194095.001]
  • [Cites] Blood. 2003 Nov 15;102(10):3759-64 [12881316.001]
  • [Cites] Immunity. 1998 Mar;8(3):363-72 [9529153.001]
  • [Cites] Eur J Immunol. 1997 Mar;27(3):750-5 [9079818.001]
  • [Cites] Nephrol Dial Transplant. 1996 Dec;11(12):2461-5 [9017623.001]
  • [Cites] Lancet. 1993 Sep 4;342(8871):575-7 [8102719.001]
  • [Cites] Arch Dis Child. 1973 Mar;48(3):207-11 [4540354.001]
  • [Cites] Blood. 2005 Aug 1;106(3):812-7 [15855274.001]
  • [Cites] Nature. 1981 Apr 2;290(5805):368-72 [6783958.001]
  • [Cites] Blood. 2006 Oct 15;108(8):2520-30 [16794250.001]
  • [Cites] N Engl J Med. 2002 Feb 21;346(8):564-9 [11856795.001]
  • [Cites] Int J Hematol. 2003 Aug;78(2):95-105 [12953802.001]
  • (PMID = 17506772.001).
  • [ISSN] 0914-7470
  • [Journal-full-title] Human cell
  • [ISO-abbreviation] Hum. Cell
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Immunoglobulin G; 0 / Immunoglobulin Light Chains; 0 / Myeloma Proteins
  •  go-up   go-down


28. Scavelli C, Nico B, Cirulli T, Ria R, Di Pietro G, Mangieri D, Bacigalupo A, Mangialardi G, Coluccia AM, Caravita T, Molica S, Ribatti D, Dammacco F, Vacca A: Vasculogenic mimicry by bone marrow macrophages in patients with multiple myeloma. Oncogene; 2008 Jan 24;27(5):663-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bone marrow macrophages of patients with active and nonactive multiple myeloma (MM), monoclonal gammopathies of undetermined significance (MGUS) and benign anemia (controls) were stimulated for 7 days with vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), and analysed for the expression of endothelial cell (EC) markers by reverse transcription (RT)-PCR, real-time RT-PCR, western blot and immunofluorescence.
  • Active MM macrophages exposed to VEGF and bFGF acquired EC markers and formed capillary-like structures mimicking paired bone marrow ECs (multiple myeloma patient-derived endothelial cells, MMECs), with major responsiveness compared to macrophages from nonactive MM, MGUS or controls.
  • These figures were rare in nonactive MM and absent in MGUS or controls.
  • Our data indicate that macrophages contribute to build neovessels in active MM through vasculogenic mimicry, and this ability proceeds parallel to progression of the plasma cell tumors.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anemia / physiopathology. Bone Marrow Cells. Case-Control Studies. Cell Culture Techniques. Disease Progression. Female. Fibroblast Growth Factor 2 / physiology. Humans. Male. Middle Aged. Paraproteinemias / physiopathology. Reverse Transcriptase Polymerase Chain Reaction. Vascular Endothelial Growth Factor A / physiology

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17667938.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A; 103107-01-3 / Fibroblast Growth Factor 2
  •  go-up   go-down


29. Sasaki H, Kato T, Murakami A, Nakayasu K, Yajima Y: [A case of monoclonal gammopathy with corneal stroma deposits]. Nippon Ganka Gakkai Zasshi; 2006 Apr;110(4):307-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of monoclonal gammopathy with corneal stroma deposits].
  • BACKGROUND: Monoclonal gammopathy is a group of disorders characterized by proliferation of a single clone of plasma cells that produce monoclonal protein.
  • Sometimes benign monoclonal gammopathy that is a symptomatic can turn into a malignancy like multiple myeloma.
  • We present a case of monoclonal gammopathy with corneal deposits which was treated with deep lamellar keratoplasty (DLKP).
  • RESULTS: We diagnosed monoclonal gammopathy in a blood test that showed elevation of serum immunoglobulin G and the Kappa chain.
  • CONCLUSIONS: Corneal deposits of unknown origin might turn into monoclonal gammopathy that could be a life-threatening disease.
  • It is important for ophthalmologists to check the whole body of a patient when finding corneal deposits.
  • [MeSH-major] Corneal Diseases / complications. Corneal Stroma / pathology. Monoclonal Gammopathy of Undetermined Significance / complications

  • MedlinePlus Health Information. consumer health - Corneal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16642949.001).
  • [ISSN] 0029-0203
  • [Journal-full-title] Nippon Ganka Gakkai zasshi
  • [ISO-abbreviation] Nippon Ganka Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


30. Schilling G, Dierlamm J, Hossfeld DK: Prognostic impact of cytogenetic aberrations in patients with multiple myeloma or monoclonal gammopathy of unknown significance. Hematol Oncol; 2005 Sep-Dec;23(3-4):102-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic impact of cytogenetic aberrations in patients with multiple myeloma or monoclonal gammopathy of unknown significance.
  • Although the yield of metaphases due to a low proliferation rate is considerably lower in plasma cell dyscrasias, a number of chromosomal changes with prognostic implications have been identified in the past years, particularly due to the introduction of new techniques.
  • This article gives a short survey of the most important genetic alterations and their prognostic influence on the outcome of patients with plasma cell malignancies known to date.
  • [MeSH-minor] Humans. Karyotyping. Leukemia / genetics. Leukemia / pathology. Leukemia / therapy. Metaphase. Plasma Cells / pathology. Prognosis. Treatment Outcome

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2005 John Wiley & Sons, Ltd.
  • (PMID = 16342296.001).
  • [ISSN] 0278-0232
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 59
  •  go-up   go-down


31. Pérez-Persona E, Mateo G, García-Sanz R, Mateos MV, de Las Heras N, de Coca AG, Hernández JM, Galende J, Martín-Nuñez G, Bárez A, Alonso JM, Martín A, López-Berges C, Orfao A, San Miguel JF, Vidriales MB: Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells. Br J Haematol; 2010 Jan;148(1):110-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells.
  • The present study explored the impact of two novel criteria; having >95% abnormal plasma cells by flow cytometry at diagnosis and the evolving subtype of the disease, as predictors of progression in 61 smouldering multiple myeloma (SMM) and 311 monoclonal gammopathy of unknown significance (MGUS) patients.
  • Although both criteria were of prognostic value, the risk of progression was better identified by immunophenotyping [Hazard Ratio (HR) 6.2 and 17.2 for SMM and MGUS, respectively] than evolving subtype, which had independent prognostic value only in MGUS (HR 3.6).
  • Immunophenotyping discriminated the different risk of progression within the evolving and non-evolving subgroups of SMM (P = 0.01) and MGUS (P < 0.001).
  • [MeSH-major] Monoclonal Gammopathy of Undetermined Significance / immunology. Multiple Myeloma / immunology. Plasma Cells / immunology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Flow Cytometry / methods. Humans. Immunophenotyping. Male. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19821821.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


32. Girón-González JA, Baturone R, Soto MJ, Márquez M, Macías I, Montes de Oca M, Medina F, Chozas N, García-Pérez S: Implications of immunomodulatory interleukins for the hyperimmunoglobulinemia of Sjögren's syndrome. Cell Immunol; 2009;259(1):56-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The levels of IL-4 were notably higher in pSS patients with monoclonal gammopathy.
  • In conclusion, patients with pSS show a state of macrophage and T-lymphocyte activation with increased concentrations of cytokines implicated in the differentiation of B cells and secretion of immunoglobulins.
  • [MeSH-major] Hypergammaglobulinemia / blood. Immunoglobulins / blood. Interleukins / blood. Sjogren's Syndrome / blood

  • MedlinePlus Health Information. consumer health - Sjogren's Syndrome.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19540455.001).
  • [ISSN] 1090-2163
  • [Journal-full-title] Cellular immunology
  • [ISO-abbreviation] Cell. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Antinuclear; 0 / Immunoglobulins; 0 / Interleukins
  •  go-up   go-down


33. Jagannath S, Kyle RA, Palumbo A, Siegel DS, Cunningham S, Berenson J: The current status and future of multiple myeloma in the clinic. Clin Lymphoma Myeloma Leuk; 2010 Feb;10(1):28-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is now recognized that all cases of multiple myeloma (MM) are preceded by the premalignant condition of monoclonal gammopathy of undetermined significance (MGUS).
  • Although patients with MGUS are generally asymptomatic and currently managed by "watch and wait," the identification of high-risk patients whose disease will progress more rapidly to smoldering MM (SMM) and MM aids in timely intervention.
  • This review highlights challenges in the clinic and newer approaches under evaluation for the treatment and/or management of patients with MGUS, SMM, and MM.
  • [MeSH-minor] Clinical Trials as Topic. Humans. Monoclonal Gammopathy of Undetermined Significance / drug therapy

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20223727.001).
  • [ISSN] 2152-2669
  • [Journal-full-title] Clinical lymphoma, myeloma & leukemia
  • [ISO-abbreviation] Clin Lymphoma Myeloma Leuk
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 148
  •  go-up   go-down


34. San Miguel JF, García-Sanz R: Prognostic features of multiple myeloma. Best Pract Res Clin Haematol; 2005;18(4):569-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Accordingly, investigation of prognostic factors may contribute to identification of risk categories and to provision of more accurate information about individual disease outcome.
  • Subsequently, biological parameters such as the proliferative activity of plasma cells and beta2-microglobulin have been added to the prognostic arsenal.
  • More recently, cytogenetic and molecular markers with significant influence on disease outcome have been identified.
  • Here we will review the most relevant prognostic factors reported in the literature in patients treated with both conventional chemotherapy and high-dose therapy followed by autologous stem-cell support, as well as in asymptomatic MM and MGUS patients.
  • [MeSH-major] Multiple Myeloma / diagnosis
  • [MeSH-minor] Hematopoietic Stem Cell Transplantation / methods. Humans. Prognosis. Risk Factors. Treatment Outcome. Tumor Burden

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16026738.001).
  • [ISSN] 1521-6926
  • [Journal-full-title] Best practice & research. Clinical haematology
  • [ISO-abbreviation] Best Pract Res Clin Haematol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 99
  •  go-up   go-down


35. Pangalis GA, Kyrtsonis MC, Kontopidou FN, Siakantaris MP, Dimopoulou MN, Vassilakopoulos TP, Tzenou T, Kokoris S, Dimitriadou E, Kalpadakis C, Tsalimalma K, Tsaftaridis P, Panayiotidis P, Angelopoulou MK: Differential diagnosis of Waldenstrom's macroglobulinemia and other B-cell disorders. Clin Lymphoma; 2005 Mar;5(4):235-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential diagnosis of Waldenstrom's macroglobulinemia and other B-cell disorders.
  • Waldenstrom's macroglobulinemia (WM) is characterized by lymphoplasmacytic infiltration of bone marrow and/or other tissues and by the presence of serum monoclonal immunoglobulin M ([IgM], without cutoff limit).
  • Differential diagnosis from other B-cell disorders (BCDs) is usually easy based on clinical, morphologic, histopathologic, immunophenotypic, and genetic features.
  • However, all BCDs potentially produce monoclonal IgM.
  • Eighty-four patients were diagnosed with WM, 5 with IgM-monoclonal gammopathy of undetermined significance (MGUS), and 41 with other BCDs (9 with B-cell chronic lymphocytic leukemia, 5 with small lymphocytic lymphoma, 14 with marginal zone lymphoma, 5 with mantle-cell lymphoma, 2 with follicular lymphoma, 2 with diffuse large B-cell lymphoma, 2 with cryoglobulinemia, and 2 with low-grade lymphoma not otherwise specified).
  • Median IgM levels were 3215 mg/dL in WM, 840 mg/dL in IgM-MGUS, and 285 mg/dL in other BCDs (5 had IgM levels > 1500 mg/dL).
  • In 10% of non-WM BCDs, monoclonal IgM was found only when more sensitive immunofixation methods were used.
  • Careful diagnosis requires the concomitant evaluation of all parameters of BCDs together.
  • Special attention should be given to mantle cell lymphoma in its atypical forms.
  • Research in this field should continue to further clarify the disease entities that overlap with WM.
  • [MeSH-major] Immunoglobulin M / analysis. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Lymphoma / diagnosis. Waldenstrom Macroglobulinemia / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Gene Expression Profiling. Humans. Lymphoma, Mantle-Cell / diagnosis. Lymphoma, Mantle-Cell / immunology. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15794855.001).
  • [ISSN] 1526-9655
  • [Journal-full-title] Clinical lymphoma
  • [ISO-abbreviation] Clin Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin M
  •  go-up   go-down


36. Zheng JM, Chen S, Zhang WQ, Pan XZ, Zhu HX, Jiang WM: [Misdiagnosis of polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, skin changes (POEMS) syndrome: a case report]. Zhonghua Gan Zang Bing Za Zhi; 2007 Aug;15(8):626-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Misdiagnosis of polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, skin changes (POEMS) syndrome: a case report].
  • [MeSH-major] Diagnostic Errors. POEMS Syndrome / diagnosis
  • [MeSH-minor] Ascites / complications. Ascites / diagnosis. Humans. Liver Cirrhosis / complications. Liver Cirrhosis / diagnosis. Male. Middle Aged

  • Genetic Alliance. consumer health - POEMS syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17711642.001).
  • [ISSN] 1007-3418
  • [Journal-full-title] Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
  • [ISO-abbreviation] Zhonghua Gan Zang Bing Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  •  go-up   go-down


37. van Rhee F: Light-chain MGUS: implications for clinical practice. Lancet; 2010 May 15;375(9727):1670-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Light-chain MGUS: implications for clinical practice.
  • [MeSH-major] Immunoglobulin Light Chains / blood. Monoclonal Gammopathy of Undetermined Significance / complications
  • [MeSH-minor] Aged. Aged, 80 and over. Humans. Middle Aged. Multiple Myeloma / etiology. Precancerous Conditions / complications. Precancerous Conditions / diagnosis. Precancerous Conditions / epidemiology. Risk Factors

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Lancet. 2010 May 15;375(9727):1721-8 [20472173.001]
  • (PMID = 20472153.001).
  • [ISSN] 1474-547X
  • [Journal-full-title] Lancet (London, England)
  • [ISO-abbreviation] Lancet
  • [Language] eng
  • [Publication-type] Comment; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulin Light Chains
  •  go-up   go-down


38. Bergón E, Miravalles E, Bergón E, Miranda I, Bergón M: The predictive power of serum kappa/lambda ratios for discrimination between monoclonal gammopathy of undetermined significance and multiple myeloma. Clin Chem Lab Med; 2005;43(1):32-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The predictive power of serum kappa/lambda ratios for discrimination between monoclonal gammopathy of undetermined significance and multiple myeloma.
  • The predictive power of serum kappa/lambda ratios on initial presentation of immunoglobulin G (IgG) or IgA monoclonal component was studied to differentiate between monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM) patients.
  • The retrospective study involved 145 patients clinically diagnosed with monoclonal gammopathy of undetermined significance or multiple myeloma, who had serum M-protein IgG <35 g/L or IgA <20 g/L at M-protein detection.
  • MM patients were considered as diseased and MGUS patients as non-diseased in order to estimate the performance characteristics of serum kappa/lambda ratios.
  • There was a statistically significant difference in kappa/lambda ratios distribution between both groups of patients, in both M-protein kappa-type (Mann-Whitney U=168, p<0.001) and in M-protein lambda-type (Mann-Whitney U=143, p<0.001).
  • Negative likelihood ratios at threshold levels of 0.6 and 4.2 were 2.17- and 3.32-fold greater, respectively, than positive likelihood ratios, so that the predictive power of a serum kappa/lambda ratio within these limits is better in ruling out (negative predictive power) than ruling in disease (positive predictive power).
  • The post-test characteristics of a serum kappa/lambda ratio interval between 0.6 and 4.2 in discriminating MGUS from MM in our geographic population were: sensitivity 0.96 (0.93-0.99 95% CI); specificity 0.70 (0.63-0.77); positive predictive value 0.68 (0.64-0.73); negative predictive value 0.96 (0.94-0.99); likelihood ratios (+)LR 3.23 (2.68-4.04); and (-)LR 17.16 (11.00-63.00).
  • Thus, serum M-protein with a kappa/lambda ratio between 0.6 and 4.2 increases the posterior probability of MGUS from 0.60 to 0.96 in asymptomatic patients, for whom only monitoring may be suggested when the serum kappa/lambda ratio is within these limits.

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Clin Chem Lab Med. 2005;43(3):349
  • (PMID = 15653439.001).
  • [ISSN] 1434-6621
  • [Journal-full-title] Clinical chemistry and laboratory medicine
  • [ISO-abbreviation] Clin. Chem. Lab. Med.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Immunoglobulin G; 0 / Immunoglobulin M; 0 / Immunoglobulin kappa-Chains; 0 / Immunoglobulin lambda-Chains; 0 / Myeloma Proteins; 0 / multiple myeloma M-proteins
  •  go-up   go-down


39. Finsterer J, Stöllberger C, Avanzini M, Rauschka H: Restrictive cardiomyopathy in dermatomyositis. Scand J Rheumatol; 2006 May-Jun;35(3):229-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In a 78-year-old male with a history of arterial hypertension, recurrent episodes of atrial fibrillation and syncopes, rupture of an infra-renal aortic aneurysm with complications (recurrent QT-prolongation, lumbo-sacral plexopathy, transient ischaemic attack, peripheral embolism), monoclonal gammopathy, subdural haematoma, focal seizures, megaloblastic anaemia, leucopenia, eosinophilia, elevated muscle enzymes and increasing tiredness, dermatomyositis was diagnosed upon clinical presentation, muscle enzyme and muscle biopsy findings.
  • Patients with dermatomyositis should undergo a comprehensive cardiological investigation as soon as the neurological diagnosis is established.


40. Shin JW, Park R, Choi TY: [A case of multiple myeloma showing marked differences in serum IgG levels between protein electrophoresis and turbidimetry]. Korean J Lab Med; 2008 Aug;28(4):282-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Serum protein level was 14.4 g/dL at the time of diagnosis.
  • According to this, we considered that both protein electrophoresis and turbidimetry should be needed to quantify serum immunoglobulins for diagnosis and follow-up of the patients with monoclonal gammopathy.
  • [MeSH-major] Immunoglobulin G / blood. Multiple Myeloma / diagnosis

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18728377.001).
  • [ISSN] 1598-6535
  • [Journal-full-title] The Korean journal of laboratory medicine
  • [ISO-abbreviation] Korean J Lab Med
  • [Language] kor
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Immunoglobulin G; 0 / Immunoglobulin kappa-Chains
  •  go-up   go-down


41. Arai M, Kusunoki S: [A case of multifocal motor neuropathy with IgM lambda anti-GM1 antibody and IgM kappa paraprotein reacting exclusively with GM2]. Rinsho Shinkeigaku; 2009 Feb-Mar;49(2-3):123-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A diagnosis of multifocal motor neuropathy was made.
  • The patient had IgM kappa monoclonal gammopathy of undetermined significance.
  • [MeSH-major] G(M1) Ganglioside / immunology. G(M2) Ganglioside / immunology. Immunoglobulin M / immunology. Immunoglobulin kappa-Chains / immunology. Immunoglobulin lambda-Chains / immunology. Motor Neuron Disease / immunology. Paraproteins / immunology

  • Genetic Alliance. consumer health - Motor neuropathy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19348179.001).
  • [ISSN] 0009-918X
  • [Journal-full-title] Rinshō shinkeigaku = Clinical neurology
  • [ISO-abbreviation] Rinsho Shinkeigaku
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Immunoglobulin M; 0 / Immunoglobulin kappa-Chains; 0 / Immunoglobulin lambda-Chains; 0 / Paraproteins; 19600-01-2 / G(M2) Ganglioside; 37758-47-7 / G(M1) Ganglioside
  •  go-up   go-down


42. Rongioletti F: Lichen myxedematosus (papular mucinosis): new concepts and perspectives for an old disease. Semin Cutan Med Surg; 2006 Jun;25(2):100-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lichen myxedematosus (papular mucinosis): new concepts and perspectives for an old disease.
  • A third group of atypical or intermediate forms, not meeting the criteria for either scleromyxedema or the localized form, includes cases of (1) scleromyxedema without monoclonal gammopathy, (2) localized forms with monoclonal gammopathy and/or systemic symptoms, (3) localized forms with mixed features of the subtypes, and (4) not well-specified cases.

  • Genetic Alliance. consumer health - Papular mucinosis.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for papular mucinosis .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16908401.001).
  • [ISSN] 1085-5629
  • [Journal-full-title] Seminars in cutaneous medicine and surgery
  • [ISO-abbreviation] Semin Cutan Med Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 21
  •  go-up   go-down


43. Wang XW, Li F: [Clinical significance of monoclonal gammopathy with undetermined significance--review]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Oct;18(5):1365-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical significance of monoclonal gammopathy with undetermined significance--review].
  • Monoclonal gammopathy with undetermined significance (MGUS) is the most common plasma cell disorder, MGUS is an asymptomatic premalignant disorder, which is markedly underdiagnosed in the general population.
  • The risk frequency of progression to multiple myeloma or a closely related plasma cell disorder was developed at a rate of 1.5% per year, indicating that the condition is not entirely benign.
  • As compared with control populations, the progression rate of MGUS into multiple myeloma, Waldenstr m's macroglobulinemia, AL amyloidosis and lymphoma were increased by 25, 46, 8.4 and 2.4 times respectively.
  • Numerous reports suggest an association of MGUS with a wide variety of other malignant and nonmalignant diseases.
  • The determining highest risk factors of progression, delaying or preventing the progression of MGUS, targeting at the highest risk of progression and improving overall quality of life, all of them are the current hot topics to be explored and summarized in this review.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21129295.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] China
  •  go-up   go-down


44. Mahapatra M, Mishra P, Makharia G, Kumar R, Saxena R: Acquired von Willebrand's disease associated with gastrointestinal angiodysplasia and monoclonal gammopathy. J Assoc Physicians India; 2006 Dec;54:963
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acquired von Willebrand's disease associated with gastrointestinal angiodysplasia and monoclonal gammopathy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17334020.001).
  • [ISSN] 0004-5772
  • [Journal-full-title] The Journal of the Association of Physicians of India
  • [ISO-abbreviation] J Assoc Physicians India
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Immunoglobulins, Intravenous
  •  go-up   go-down


45. Wiedermann CJ, Kob M, Benvenuti S, Carella R, Lucchin L, Piazzi L, Chilovi F, Mazzoleni G: Digital clubbing in primary intestinal lymphangiectasia: a case report. Wien Med Wochenschr; 2010 Aug;160(15-16):431-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary intestinal lymphangiectasia (PIL), also known as Waldmann's disease, is a rare disorder characterized by dilated intestinal lacteals resulting in lymph leakage into the small bowel lumen and responsible for protein-losing enteropathy leading to lymphopenia, hypoalbuminemia and hypogammaglobulinemia.
  • We report a case of secondary hyperparathyroidism, osteopenia, monoclonal gammopathy and digital clubbing in a 57-year-old patient with a 12-year history of discontinuous diarrhea.
  • [MeSH-minor] Biopsy. Combined Modality Therapy. Diet, Fat-Restricted. Double-Balloon Enteroscopy. Enteral Nutrition. Food, Formulated. Humans. Intestine, Small / pathology. Lymphangiectasis, Intestinal / diagnosis. Lymphangiectasis, Intestinal / diet therapy. Lymphangiectasis, Intestinal / pathology. Lymphedema / diagnosis. Lymphedema / diet therapy. Lymphedema / pathology. Male. Middle Aged. Protein-Losing Enteropathies / diagnosis. Protein-Losing Enteropathies / diet therapy. Protein-Losing Enteropathies / pathology

  • Genetic Alliance. consumer health - Lymphangiectasis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1964 Apr 9;270:761-6 [14107315.001]
  • [Cites] Lancet. 1987 Dec 19;2(8573):1434-5 [2891996.001]
  • [Cites] Digestion. 1994;55(1):59-64 [7509299.001]
  • [Cites] Arch Surg. 1986 May;121(5):530-4 [3707330.001]
  • [Cites] Am J Gastroenterol. 1990 Oct;85(10):1398-402 [2220736.001]
  • [Cites] J Clin Invest. 2006 Aug;116(8):2142-2151 [16841095.001]
  • [Cites] Breast J. 2005 Sep-Oct;11(5):360 [16174162.001]
  • [Cites] Clin Exp Dermatol. 1991 Mar;16(2):124-6 [2032374.001]
  • [Cites] Expert Opin Drug Metab Toxicol. 2009 Aug;5(8):971-9 [19611401.001]
  • [Cites] Ann Med Interne (Paris). 2000 Oct;151(6):511-2 [11104932.001]
  • [Cites] Immunity. 2004 Jun;20(6):769-83 [15189741.001]
  • [Cites] Gut. 2000 Aug;47(2):296-300 [10896925.001]
  • [Cites] Orphanet J Rare Dis. 2008 Feb 22;3:5 [18294365.001]
  • [Cites] Med Lab Sci. 1989 Jan;46(1):79-80 [2779388.001]
  • [Cites] J Paediatr Child Health. 1999 Jun;35(3):260-3 [10404446.001]
  • [Cites] Nutrition. 2000 Apr;16(4):303-4 [10758368.001]
  • [Cites] N Engl J Med. 1979 Mar 15;300(11):605-6 [763272.001]
  • [Cites] Ann Dermatol Venereol. 2006 Aug-Sep;133(8-9 Pt 1):693-6 [17053741.001]
  • [Cites] Br Med J. 1979 Oct 6;2(6194):825-8 [509114.001]
  • [Cites] J Pathol. 2004 Jun;203(2):721-8 [15141388.001]
  • [Cites] J Health Popul Nutr. 2001 Sep;19(3):204-8 [11761775.001]
  • [Cites] Br J Dermatol. 2002 Jan;146(1):134-7 [11841381.001]
  • [Cites] Rev Esp Enferm Dig. 2004 Apr;96(4):259-64 [15117239.001]
  • [Cites] Annu Rev Immunol. 2010;28:573-621 [20192811.001]
  • [Cites] Br J Dermatol. 1964 Apr;76:153-7 [14140738.001]
  • [Cites] J Gastroenterol Hepatol. 2008 Jul;23(7 Pt 2):e88-95 [18005011.001]
  • [Cites] Gut. 1981 Mar;22(3):203-6 [7227854.001]
  • (PMID = 20812055.001).
  • [ISSN] 1563-258X
  • [Journal-full-title] Wiener medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Wien Med Wochenschr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] Waldmann disease
  •  go-up   go-down


46. Denguir H, Ben-Hamda K, Gharbi M, Addad F, Hammami S, Mlika A, Abbes F, Moussa A, Betbout F, Gamra H, Maatouk F, Dridi Z, Zakhama A, Mahjoub S, Ben-Farhat M: [Cardiac amyloidosis revealing multiple myeloma]. Tunis Med; 2005 May;83(5):300-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Amyloidosis is a rare disease characterized by an extracellular accumulation of a protein polysaccharid complex (Amyloid).
  • Cardiac involvement is considered as a major prognostic factor.
  • The diagnosis of cardiac amyloidosis was suggested by echocardiography: Left ventricular concentric hypertrophy and typical amyeloid infiltration with hyperechoic, shiny and granite-like aspect of the interventricular septum.
  • This cardiac amyloidosis was secondary to multiple myeloma: monoclonal Gammopathy with immunoglobulin Lambda in the first and Kappa in the second, and the presence of a plasmocyte infiltration in the sternal puncture.
  • [MeSH-major] Amyloidosis / etiology. Heart Diseases / etiology. Multiple Myeloma / complications. Multiple Myeloma / diagnosis


47. Beyer M, Kochanek M, Giese T, Endl E, Weihrauch MR, Knolle PA, Classen S, Schultze JL: In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma. Blood; 2006 May 15;107(10):3940-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In healthy individuals, T(reg) cells consist not only of memory but also of naive T cells, which can undergo peripheral expansion and are characterized by a relative enrichment for autoreactive T-cell receptors.
  • Here, we demonstrate in patients with premalignant monoclonal gammopathy of undetermined significance and patients with multiple myeloma that functional FoxP3(+) T(reg) cells of naive, central, and effector memory phenotype as determined by CCR7 and CD45RA expression are significantly expanded.
  • Low frequencies of T-cell receptor excision circles in naive T(reg) cells in both healthy controls and multiple myeloma patients point to peripheral expansion as the prominent mechanism of increased frequencies of naive T(reg) cells in these cancer patients.
  • [MeSH-minor] Antigens, CD / blood. Antigens, CD / genetics. Antigens, CD45 / blood. Antigens, CD45 / genetics. Flow Cytometry. Humans. Receptors, Antigen, T-Cell / blood. Receptors, Antigen, T-Cell / immunology. Receptors, CCR7. Receptors, Chemokine / blood. Receptors, Chemokine / genetics

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16410445.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / CCR7 protein, human; 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors; 0 / Receptors, Antigen, T-Cell; 0 / Receptors, CCR7; 0 / Receptors, Chemokine; 0 / Receptors, Interleukin-2; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


48. Spisek R, Kukreja A, Chen LC, Matthews P, Mazumder A, Vesole D, Jagannath S, Zebroski HA, Simpson AJ, Ritter G, Durie B, Crowley J, Shaughnessy JD Jr, Scanlan MJ, Gure AO, Barlogie B, Dhodapkar MV: Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy. J Exp Med; 2007 Apr 16;204(4):831-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy.
  • Specific targets of cellular immunity in human premalignancy are largely unknown.
  • Monoclonal gammopathy of undetermined significance (MGUS) represents a precursor lesion to myeloma (MM).
  • We show that antigenic targets of spontaneous immunity in MGUS differ from MM.
  • MGUS patients frequently mount a humoral and cellular immune response against SOX2, a gene critical for self-renewal in embryonal stem cells.
  • Intranuclear expression of SOX2 marks the clonogenic CD138(-) compartment in MGUS.
  • Cellular immunity to SOX2 inhibits the clonogenic growth of MGUS cells in vitro.
  • Detection of anti-SOX2 T cells predicts favorable clinical outcome in patients with asymptomatic plasmaproliferative disorders.

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Exp Med. 2003 Dec 1;198(11):1623-6 [14638849.001]
  • [Cites] J Exp Med. 2003 Dec 1;198(11):1753-7 [14638846.001]
  • [Cites] Hematol J. 2003;4(6):379-98 [14671610.001]
  • [Cites] Cancer Res. 2004 Feb 15;64(4):1546-58 [14989251.001]
  • [Cites] Blood. 2004 Mar 15;103(6):2332-6 [14630803.001]
  • [Cites] Science. 2004 Jul 9;305(5681):200-5 [15247469.001]
  • [Cites] N Engl J Med. 2004 Aug 12;351(7):657-67 [15306667.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] Cancer Cell. 2004 Dec;6(6):531-3 [15607956.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Feb 22;102(8):2910-5 [15703291.001]
  • [Cites] Clin Cancer Res. 2005 Feb 15;11(4):1521-6 [15746055.001]
  • [Cites] Cancer Immunol Immunother. 2005 May;54(5):409-13 [15602654.001]
  • [Cites] Annu Rev Immunol. 2005;23:487-513 [15771579.001]
  • [Cites] J Exp Med. 2005 May 2;201(9):1503-17 [15867097.001]
  • [Cites] Cancer. 2005 Jun 15;103(12):2575-83 [15880380.001]
  • [Cites] Methods Mol Med. 2005;103:207-16 [15542909.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9601-6 [15983380.001]
  • [Cites] Clin Adv Hematol Oncol. 2004 Aug;2(8):507, 509 [16163229.001]
  • [Cites] Cell. 2005 Sep 23;122(6):947-56 [16153702.001]
  • [Cites] Trends Neurosci. 2005 Nov;28(11):583-8 [16139372.001]
  • [Cites] Nat Rev Cancer. 2006 Jan;6(1):24-37 [16397525.001]
  • [Cites] N Engl J Med. 2006 Mar 30;354(13):1362-9 [16571879.001]
  • [Cites] Hematol Oncol Clin North Am. 2006 Jun;20(3):735-50 [16762732.001]
  • [Cites] J Exp Med. 2006 Aug 7;203(8):1859-65 [16880256.001]
  • [Cites] Cell. 2006 Aug 25;126(4):663-76 [16904174.001]
  • [Cites] Leukemia. 2006 Sep;20(9):1467-73 [16855634.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4198-203 [10760287.001]
  • [Cites] Cancer Res. 2000 May 15;60(10):2571-5 [10825122.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):105-11 [11689955.001]
  • [Cites] J Exp Med. 2002 Jan 7;195(1):125-33 [11781371.001]
  • [Cites] Nat Immunol. 2002 Nov;3(11):991-8 [12407406.001]
  • [Cites] Cancer Sci. 2003 Feb;94(2):135-41 [12708487.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15178-83 [14645703.001]
  • (PMID = 17389240.001).
  • [ISSN] 0022-1007
  • [Journal-full-title] The Journal of experimental medicine
  • [ISO-abbreviation] J. Exp. Med.
  • [Language] ENG
  • [Grant] United States / NCCIH NIH HHS / AT / P50 AT002779; United States / NCRR NIH HHS / RR / M01 RR000102; United States / NCI NIH HHS / CA / P01-CA55819; United States / NCI NIH HHS / CA / CA106802; United States / NCI NIH HHS / CA / CA109465; United States / NCI NIH HHS / CA / R01 CA106802; United States / NCCIH NIH HHS / AT / P50-AT02779; United States / NCI NIH HHS / CA / R01 CA109465; United States / NCI NIH HHS / CA / P01 CA055819; United States / NCRR NIH HHS / RR / M01-RR00102
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / HMGB Proteins; 0 / Immunoglobulin G; 0 / SOX2 protein, human; 0 / SOXB1 Transcription Factors; 0 / Transcription Factors
  • [Other-IDs] NLM/ PMC2118551
  •  go-up   go-down


49. Scarlato M, Previtali SC, Carpo M, Pareyson D, Briani C, Del Bo R, Nobile-Orazio E, Quattrini A, Comi GP: Polyneuropathy in POEMS syndrome: role of angiogenic factors in the pathogenesis. Brain; 2005 Aug;128(Pt 8):1911-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In order to clarify the role of angiogenic factors in polyneuropathy of POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, skin changes) syndrome, we measured the serum concentrations of vascular endothelial growth factor (VEGF) and erythropoietin (EPO) in 11 patients and correlated these with VEGF and EPO peripheral nerve expression and the degree of endoneurial vessel involvement.
  • Similarly, in POEMS nerves VEGF was highly expressed in blood vessels and some non-myelin-forming Schwann cells.
  • In conclusion, establishing the role of angiogenic factors in polyneuropathy may lead to a better understanding of the effects of VEGF and EPO on microangiopathy and Schwann cell function.

  • Genetic Alliance. consumer health - POEMS syndrome.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15975949.001).
  • [ISSN] 1460-2156
  • [Journal-full-title] Brain : a journal of neurology
  • [ISO-abbreviation] Brain
  • [Language] eng
  • [Grant] Italy / Telethon / / GGP030193; Italy / Telethon / / GTF02008
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Receptors, Erythropoietin; 0 / Transcription Factors; 0 / Vascular Endothelial Growth Factor A; 11096-26-7 / Erythropoietin; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  •  go-up   go-down


50. Niermeijer JM, Eurelings M, Lokhorst HL, van der Pol WL, Franssen H, Wokke JH, Notermans NC: Rituximab for polyneuropathy with IgM monoclonal gammopathy. J Neurol Neurosurg Psychiatry; 2009 Sep;80(9):1036-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab for polyneuropathy with IgM monoclonal gammopathy.
  • BACKGROUND: Polyneuropathy with IgM monoclonal gammopathy can be a disabling disorder necessitating treatment.
  • METHODS: In a prospective open label trial, 17 patients with disabling IgM MGUS polyneuropathy were treated with rituximab, a chimeric anti-CD-20 monoclonal antibody.
  • Bone marrow investigations showed CD 20 B cell depletion in all patients.
  • The presence of anti-MAG and a disease duration shorter than 10 years may predict treatment response.
  • CONCLUSION: Rituximab is a candidate for treatment of IgM MGUS polyneuropathy and should be further investigated in a double-blind randomised trial.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Immunoglobulin M / immunology. Immunologic Factors / therapeutic use. Paraproteinemias / drug therapy. Paraproteinemias / immunology
  • [MeSH-minor] Age of Onset. Anti-Inflammatory Agents / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antigens, CD20 / metabolism. B-Lymphocytes / immunology. Bone Marrow Cells / physiology. Cyclophosphamide / therapeutic use. Disability Evaluation. Female. Humans. Immunosuppressive Agents / therapeutic use. Lymphocyte Count. Male. Middle Aged. Muscle Strength / physiology. Neural Conduction / physiology. Prednisone / therapeutic use. Prospective Studies. Rituximab. Sensation / physiology. Treatment Outcome. Vidarabine / analogs & derivatives. Vidarabine / therapeutic use

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19684235.001).
  • [ISSN] 1468-330X
  • [Journal-full-title] Journal of neurology, neurosurgery, and psychiatry
  • [ISO-abbreviation] J. Neurol. Neurosurg. Psychiatry
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Immunoglobulin M; 0 / Immunologic Factors; 0 / Immunosuppressive Agents; 4F4X42SYQ6 / Rituximab; 8N3DW7272P / Cyclophosphamide; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; VB0R961HZT / Prednisone
  •  go-up   go-down


51. Kristinsson SY, Goldin LR, Björkholm M, Turesson I, Landgren O: Risk of solid tumors and myeloid hematological malignancies among first-degree relatives of patients with monoclonal gammopathy of undetermined significance. Haematologica; 2009 Aug;94(8):1179-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of solid tumors and myeloid hematological malignancies among first-degree relatives of patients with monoclonal gammopathy of undetermined significance.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Mar 1;95(5):1869-71 [10688850.001]
  • [Cites] J Urol. 2001 Dec;166(6):2129-33 [11696721.001]
  • [Cites] N Engl J Med. 2002 Feb 21;346(8):564-9 [11856795.001]
  • [Cites] Br J Haematol. 2003 Jun;121(5):749-57 [12780789.001]
  • [Cites] Blood. 2003 Nov 15;102(10):3759-64 [12881316.001]
  • [Cites] Blood. 2009 Jul 23;114(4):791-5 [19182202.001]
  • [Cites] Cancer. 1985 Oct 15;56(8):2133-9 [4027940.001]
  • [Cites] N Engl J Med. 2006 Mar 30;354(13):1362-9 [16571879.001]
  • [Cites] Int J Cancer. 2006 Jun 15;118(12):3095-8 [16395700.001]
  • [Cites] N Engl J Med. 2008 Jul 10;359(2):152-7 [18614782.001]
  • [Cites] N Engl J Med. 2008 Oct 16;359(16):1734-5; author reply 1735 [18923179.001]
  • [Cites] Ann Hematol. 2004 Oct;83(10):658-60 [15278296.001]
  • (PMID = 19546435.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Letter; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2719044
  •  go-up   go-down


52. de Seigneux S, Bindi P, Debiec H, Alyanakian MA, Aymard B, Callard P, Ronco P, Aucouturier P: Immunoglobulin deposition disease with a membranous pattern and a circulating monoclonal immunoglobulin G with charge-dependent aggregation properties. Am J Kidney Dis; 2010 Jul;56(1):117-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoglobulin deposition disease with a membranous pattern and a circulating monoclonal immunoglobulin G with charge-dependent aggregation properties.
  • A 62-year-old woman presented with nephrotic syndrome, monoclonal gammopathy, and membranous-like nephropathy with nonorganized deposits composed of monoisotypic immunoglobulin G1 lambda protein.
  • Nephrotic syndrome remitted after a brief course of treatment with melphalan despite ongoing production of the monoclonal protein.
  • The circulating monoclonal immunoglobulin G1 lambda showed unusual in vitro aggregation properties, including dependence on low ionic strength and neutral pH, suggesting that electrostatic interactions had a role in the precipitation process.
  • This case illustrates the importance of looking for monoclonal immunoglobulin deposits when kidney biopsy findings are suggestive of membranous nephropathy.
  • [MeSH-major] Glomerulonephritis, Membranous / blood. Glomerulonephritis, Membranous / diagnosis. Immunoglobulin G / blood. Monoclonal Gammopathy of Undetermined Significance / blood. Monoclonal Gammopathy of Undetermined Significance / diagnosis
  • [MeSH-minor] Female. Humans. Middle Aged. Paraproteinemias / blood. Paraproteinemias / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20471736.001).
  • [ISSN] 1523-6838
  • [Journal-full-title] American journal of kidney diseases : the official journal of the National Kidney Foundation
  • [ISO-abbreviation] Am. J. Kidney Dis.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin G
  •  go-up   go-down


53. Schuster C, Kränke B, Aberer E, Arbab E, Sturm G, Aberer W: Schnitzler syndrome: response to anakinra in two cases and a review of the literature. Int J Dermatol; 2009 Nov;48(11):1190-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Schnitzler syndrome is a rare disease characterized by a chronic urticarial eruption and monoclonal gammopathy, as well as clinical and laboratory signs of inflammation.
  • The pathophysiology is still unknown, although various autoantibody-mediated mechanisms have been described.
  • RESULTS: We report two cases of nearly complete remission of symptoms in Schnitzler syndrome after the initiation of anakinra therapy, and the first observation of a relapse under continuous daily anakinra therapy.

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20064173.001).
  • [ISSN] 1365-4632
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antirheumatic Agents; 0 / Interleukin 1 Receptor Antagonist Protein
  • [Number-of-references] 35
  •  go-up   go-down


54. Dispenzieri A, Katzmann JA, Kyle RA, Larson DR, Melton LJ 3rd, Colby CL, Therneau TM, Clark R, Kumar SK, Bradwell A, Fonseca R, Jelinek DF, Rajkumar SV: Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet; 2010 May 15;375(9727):1721-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study.
  • BACKGROUND: Monoclonal gammopathy of undetermined significance (MGUS) is defined by expression of heavy-chain immunoglobulin (IgH) and is the precursor lesion for 80% of cases of multiple myeloma.
  • The remaining 20% are characterised by absence of IgH expression; we aimed to assess prevalence of a corresponding precursor entity, light-chain MGUS.
  • METHODS: We used a population-based cohort, previously assembled to estimate MGUS prevalence, of 21,463 residents of Olmsted County, MN, USA, aged 50 years and older.
  • Light-chain MGUS was defined as an abnormal free light-chain ratio with no IgH expression, plus increased concentration of the involved light chain.
  • We calculated age-specific and sex-specific prevalence and rates of progression to lymphoproliferative disorders for light-chain and conventional MGUS and assessed incidence of renal disorders in patients with light-chain MGUS.
  • FINDINGS: 610 (3.3%) of 18,357 people tested had an abnormal free light-chain ratio, of whom 213 had IgH expression that was diagnostic of conventional MGUS.
  • 146 of the remaining 397 individuals had an increase of at least one free light chain and met criteria for light-chain MGUS.
  • Prevalence of light-chain MGUS was 0.8% (95% CI 0.7-0.9), contributing to an overall MGUS prevalence of 4.2% (3.9-4.5).
  • Risk of progression to multiple myeloma in patients with light-chain MGUS was 0.3% (0.1-0.8) per 100 person-years.
  • 30 (23%) of 129 patients with light-chain MGUS were diagnosed with renal disease.
  • INTERPRETATION: We define a clinical entity representing the light-chain equivalent of conventional MGUS and posing a risk of progression to light-chain multiple myeloma and related disorders.

  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • [Cites] Clin Chem. 2002 Sep;48(9):1437-44 [12194920.001]
  • [Cites] N Engl J Med. 2002 Feb 21;346(8):564-9 [11856795.001]
  • [Cites] Lancet. 2003 Feb 8;361(9356):489-91 [12583950.001]
  • [Cites] Clin Lab. 2003;49(1-2):25-7 [12593472.001]
  • [Cites] Br J Haematol. 2003 Jun;121(5):749-57 [12780789.001]
  • [Cites] Blood. 2004 May 15;103(10):3869-75 [14715636.001]
  • [Cites] Am J Med. 1978 May;64(5):814-26 [645746.001]
  • [Cites] N Engl J Med. 1982 Mar 11;306(10):564-7 [7057813.001]
  • [Cites] Osteoporos Int. 1998;8(1):68-74 [9692080.001]
  • [Cites] Cancer. 2004 Dec 1;101(11):2667-74 [15481060.001]
  • [Cites] Blood. 2005 Aug 1;106(3):812-7 [15855274.001]
  • [Cites] Blood. 2006 Feb 1;107(3):904-6 [16210333.001]
  • [Cites] N Engl J Med. 2006 Mar 30;354(13):1362-9 [16571879.001]
  • [Cites] Mayo Clin Proc. 2006 Dec;81(12):1575-8 [17165636.001]
  • [Cites] Haematologica. 2007 Aug;92(8):1135-8 [17650446.001]
  • [Cites] Clin J Am Soc Nephrol. 2008 Nov;3(6):1684-90 [18945993.001]
  • [Cites] Blood. 2009 May 28;113(22):5412-7 [19179464.001]
  • [Cites] Blood. 2009 May 28;113(22):5418-22 [19234139.001]
  • [Cites] Clin Chem. 2009 Aug;55(8):1517-22 [19520758.001]
  • [Cites] Mayo Clin Proc. 2009 Aug;84(8):685-93 [19648385.001]
  • [Cites] Blood. 2009 Dec 3;114(24):4928-32 [19828698.001]
  • [Cites] Mayo Clin Proc. 2003 Jan;78(1):21-33 [12528874.001]
  • [Cites] Blood. 2001 May 1;97(9):2900-2 [11313287.001]
  • [Cites] Clin Chem. 2001 Apr;47(4):673-80 [11274017.001]
  • [CommentIn] Lancet. 2010 Oct 9;376(9748):1221; author reply 1221-2 [20934591.001]
  • [CommentIn] Lancet. 2010 Oct 9;376(9748):1221; author reply 1221-2 [20934589.001]
  • [CommentIn] Lancet. 2010 Oct 9;376(9748):1220; author reply 1221-2 [20934588.001]
  • [CommentIn] Lancet. 2010 May 15;375(9727):1670-1 [20472153.001]
  • [ErratumIn] Lancet. 2010 Jul 31;376(9738):332
  • (PMID = 20472173.001).
  • [ISSN] 1474-547X
  • [Journal-full-title] Lancet (London, England)
  • [ISO-abbreviation] Lancet
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA083724; United States / NCI NIH HHS / CA / R01 CA107476-08; United States / NCI NIH HHS / CA / CA100707-05; United States / NCI NIH HHS / CA / R01 CA083724-06; United States / NCI NIH HHS / CA / CA083724-06; United States / NCI NIH HHS / CA / P50 CA100707-05; United States / NCI NIH HHS / CA / R01 CA100080; United States / NCI NIH HHS / CA / CA093842-03; United States / NCI NIH HHS / CA / CA107476-08; United States / NCI NIH HHS / CA / CA93842; United States / NCI NIH HHS / CA / P01 CA062242-14; United States / NCI NIH HHS / CA / R01 CA125614-05; United States / NCI NIH HHS / CA / CA 125614; United States / NIAMS NIH HHS / AR / AR030582-44; United States / NCI NIH HHS / CA / R01 CA100080-04; United States / NCI NIH HHS / CA / R01 CA093842; United States / NCI NIH HHS / CA / CA100080; United States / NIAMS NIH HHS / AR / AR30582; United States / NIAMS NIH HHS / AR / R01 AR030582-44; United States / NCI NIH HHS / CA / P01 CA062242; United States / NCI NIH HHS / CA / CA150831; United States / NCI NIH HHS / CA / R01 CA125614; United States / NCI NIH HHS / CA / CA062242; United States / NCI NIH HHS / CA / P50 CA100707; United States / NCI NIH HHS / CA / CA100707; United States / NCI NIH HHS / CA / CA83724; United States / NIAMS NIH HHS / AR / R01 AR030582; United States / NIAMS NIH HHS / AR / R01 AR030582-34; United States / NCI NIH HHS / CA / CA062242-14; United States / NCI NIH HHS / CA / R01 CA093842-03; United States / NCI NIH HHS / CA / CA100080-04; United States / NCI NIH HHS / CA / R01 CA107476; United States / NCI NIH HHS / CA / CA107476
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulin Light Chains; 0 / Immunoglobulin kappa-Chains; 0 / Immunoglobulin lambda-Chains
  • [Other-IDs] NLM/ NIHMS211720; NLM/ PMC2904571
  •  go-up   go-down


55. Varella TC, Nishimura MY, Machado MC, de Moraes-Vasconcelos D, Rivitti EA: Schnitzler's syndrome without monoclonal gammopathy. Acta Derm Venereol; 2005;85(3):272-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Schnitzler's syndrome without monoclonal gammopathy.
  • [MeSH-major] Arthralgia / diagnosis. Immunoglobulin M
  • [MeSH-minor] Adult. Anti-Inflammatory Agents, Non-Steroidal / administration & dosage. Diagnosis, Differential. Drug Therapy, Combination. Humans. Male. Prednisone / administration & dosage. Syndrome. Thalidomide / administration & dosage. Urticaria / etiology. Urticaria / pathology

  • Hazardous Substances Data Bank. THALIDOMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16040423.001).
  • [ISSN] 0001-5555
  • [Journal-full-title] Acta dermato-venereologica
  • [ISO-abbreviation] Acta Derm. Venereol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Immunoglobulin M; 4Z8R6ORS6L / Thalidomide; VB0R961HZT / Prednisone
  •  go-up   go-down


56. Suurmeijer AJ: Papillary hemangiomas and glomeruloid hemangiomas are distinct clinicopathological entities. Int J Surg Pathol; 2010 Feb;18(1):48-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thin basement membranes and glomeruloid architecture are typical of glomeruloid hemangiomas, whereas papillae with thick mantles of a basement membrane- like matrix enveloping pericytes are prominent in papillary hemangiomas.
  • This additional technique should allow pathologists to readily distinguish between the lesions and make a proper diagnosis.
  • What is important is that glomeruloid hemangiomas-often presenting in a spectrum of multiple cutaneous vascular lesions, including cherry hemangiomas-are a hallmark of POEMS (acronym for polyneuropathy, oganomegaly, endocrinopathy, monoclonal gammopathy, and skin changes) syndrome and/or multicentric Castleman's disease, whereas papillary hemangiomas clinically present as innocent solitary cutaneous hemangiomas in otherwise healthy individuals.

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18805868.001).
  • [ISSN] 1940-2465
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


57. Brown LM, Gridley G, Check D, Landgren O: Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders. Blood; 2008 Apr 1;111(7):3388-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders.
  • In a retrospective cohort of more than 4 million white and black male United States (US) veterans, we explored the role of specific prior autoimmune, infectious, inflammatory, and allergic disorders in the etiology of multiple myeloma (MM) and monoclonal gammopathy of undetermined significance (MGUS).
  • The analysis included 4641 patients (3040 white, 1601 black) and 2046 patients (1312 white; 734 black) with a discharge diagnosis of MM and MGUS, respectively.
  • Using Poisson regression, we calculated age-adjusted relative risks (RRs) and 95% confidence intervals (CIs) for the relationship between MM, MGUS, and specific prior medical conditions.
  • Risks for MGUS were generally of similar magnitude.
  • Our results indicate that various types of immune-mediated conditions might act as triggers for MM/MGUS development.


58. Hamidou MA, Belizna C, Wiertlewsky S, Audrain M, Biron C, Grolleau JY, Mussini JM: Intravenous cyclophosphamide in refractory polyneuropathy associated with IgM monoclonal gammopathy: an uncontrolled open trial. Am J Med; 2005 Apr;118(4):426-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intravenous cyclophosphamide in refractory polyneuropathy associated with IgM monoclonal gammopathy: an uncontrolled open trial.

  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15808143.001).
  • [ISSN] 0002-9343
  • [Journal-full-title] The American journal of medicine
  • [ISO-abbreviation] Am. J. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin M; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


59. Batuecas Mohedano M, Piqueras Argüello JA, Carballo Alvarez F, Parra Cid T, Larrubia Marfil JR, Vinssac Gil JL, Granizo Domínguez V: [Monoclonal gammopathy: a frequently overlooked diagnosis]. Rev Clin Esp; 2005 May;205(5):207-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Monoclonal gammopathy: a frequently overlooked diagnosis].
  • [Transliterated title] Gammapatía monoclonal: un diagnóstico frecuentemente soslayado.
  • OBJECTIVE: To know the rate of occurrence of monoclonal bands in a clinical laboratory as an estimate of monoclonal gammopathy incidence, and to detect the proportion of these bands in which an explicit clinical diagnosis or follow-up request is not established.
  • PATIENTS AND METHODS: 200 patients were studied in which a monoclonal band had been detected de novo.
  • Most frequent diagnosis in the group of patients with a diagnosis was monoclonal gammopathy with uncertain meaning.
  • DISCUSSION: The data suggest a lack of clinical effort when the result is the appearance of a monoclonal band.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15970150.001).
  • [ISSN] 0014-2565
  • [Journal-full-title] Revista clínica española
  • [ISO-abbreviation] Rev Clin Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


60. Kastritis E, Katoulis A, Terpos E, Panayiotides I, Gavriatopoulopu M, Dimopopoulos MA: Schnitzler's syndrome: increased levels of bone formation and angiogenesis factors are reduced after successful pefloxacin treatment. Clin Lymphoma Myeloma; 2008 Dec;8(6):359-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Schnitzler's syndrome is characterized by chronic urticaria and monoclonal immunoglobulin (Ig) M gammopathy, with other features including intermittent fever, joint and/or bone pain with radiologic evidence of osteosclerosis, lymphadenopathy, enlarged liver and/or spleen, leukocytosis, and elevated erythrocyte sedimentation rate.
  • Bone metabolism and angiogenesis markers are deregulated in Waldenström macroglobulinemia and IgM monoclonal gammopathy of unknown significance, but these markers have not been assessed in Schnitzler's syndrome.
  • High bone turnover and strikingly elevated levels of angiogenic cytokines were observed at diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19064402.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inducing Agents; 0 / Anti-Infective Agents; 2H52Z9F2Q5 / Pefloxacin
  •  go-up   go-down


61. Kim DW, Lee BI, Park SH: Accelerated healing of pyoderma gangrenosum in Behçet patient treated with cyclosporine and split thickness skin graft. Ann Plast Surg; 2008 Nov;61(5):552-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pyoderma gangrenosum is a dermatologic manifestation of systemic disease such as inflammatory bowel disease, monoclonal gammopathy, arthritis, malignancies, and Behçet's disease.

  • Genetic Alliance. consumer health - Pyoderma gangrenosum.
  • MedlinePlus Health Information. consumer health - Behcet's Syndrome.
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18948785.001).
  • [ISSN] 1536-3708
  • [Journal-full-title] Annals of plastic surgery
  • [ISO-abbreviation] Ann Plast Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antifungal Agents; 83HN0GTJ6D / Cyclosporine
  •  go-up   go-down


62. Handa U, Chhabra S, Mohan H: Plasma cell tumours: cytomorphological features in a series of 12 cases diagnosed on fine needle aspiration cytology. Cytopathology; 2010 Jun;21(3):186-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma cell tumours: cytomorphological features in a series of 12 cases diagnosed on fine needle aspiration cytology.
  • OBJECTIVE: Plasma cell tumours represent autonomous proliferation of plasma cells and can manifest as multiple myeloma, monoclonal gammopathy of undetermined significance, variants of plasma cell myeloma or plasmacytoma.
  • METHODS: We report 12 cases of plasma cell tumours, which were initially diagnosed as plasmacytoma on fine needle aspiration cytology (FNAC).
  • RESULTS: The cytological smears from all cases were cellular and showed numerous plasma cells in varying degrees of maturity.
  • In the remaining two cases, bone marrow and urine examination findings were not available, so a conclusive diagnosis of multiple myeloma or solitary plasmacytoma could not be made.
  • CONCLUSION: The study highlights the role of FNAC in the diagnosis of plasma cell tumours.
  • [MeSH-major] Plasma Cells / pathology. Plasmacytoma / diagnosis. Plasmacytoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19416310.001).
  • [ISSN] 1365-2303
  • [Journal-full-title] Cytopathology : official journal of the British Society for Clinical Cytology
  • [ISO-abbreviation] Cytopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


63. Decaux O, Avet-Loiseau H, Grosbois B: [Malignant transformation of monoclonal gammopathy of undetermined significance]. Presse Med; 2007 Dec;36(12 Pt 3):1985-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant transformation of monoclonal gammopathy of undetermined significance].
  • [Transliterated title] Transformation maligne des gammapathies monoclonales de signification indéterminée.
  • Monoclonal gammopathy of undetermined significance (MGUS) is found in approximately 3% of the general population aged 50 years or older.
  • MGUS is a premalignant state.
  • Some factors predictive of malignant transformation have been identified: type of serum monoclonal protein, monoclonal protein value, bone marrow plasmocytosis and serum free light chain ratio.
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Bone Marrow / pathology. Cell Transformation, Neoplastic. Cohort Studies. Diagnosis, Differential. Female. Follow-Up Studies. Genetic Markers. Humans. Immunoglobulin A / immunology. Immunoglobulin G / immunology. Immunoglobulin Isotypes. Immunoglobulin M / immunology. Leukemia, Lymphocytic, Chronic, B-Cell / etiology. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / etiology. Lymphoma, Non-Hodgkin / immunology. Male. Middle Aged. Multiple Myeloma / diagnosis. Multiple Myeloma / etiology. Multiple Myeloma / immunology. Multiple Myeloma / pathology. Myelography. Plasma Cells. Predictive Value of Tests. Retrospective Studies. Risk Factors. Time Factors. Waldenstrom Macroglobulinemia / diagnosis. Waldenstrom Macroglobulinemia / immunology. Waldenstrom Macroglobulinemia / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17509811.001).
  • [ISSN] 0755-4982
  • [Journal-full-title] Presse medicale (Paris, France : 1983)
  • [ISO-abbreviation] Presse Med
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Genetic Markers; 0 / Immunoglobulin A; 0 / Immunoglobulin G; 0 / Immunoglobulin Isotypes; 0 / Immunoglobulin M
  • [Number-of-references] 61
  •  go-up   go-down


64. Casula S, Zolotarev AS, Stuart-Tilley AK, Wilhelm S, Shmukler BE, Brugnara C, Alper SL: Chemical crosslinking studies with the mouse Kcc1 K-Cl cotransporter. Blood Cells Mol Dis; 2009 May-Jun;42(3):233-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • More extensive studies were performed with the amine-reactive disuccinyl suberate (DSS) and with the sulfhydryl-reactive bis-maleimidohexane (BMH).
  • DSS and BMH each inhibited KCC1-mediated (86)Rb(+) uptake stimulated by hypotonicity or by N-ethylmaleimide (NEM) without reduction in nominal surface abundance of KCC1.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • Xenbase. Xenbase .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2002 Mar 29;277(13):11090-6 [11792708.001]
  • [Cites] Biochemistry. 2008 Dec 23;47(51):13674-85 [19035652.001]
  • [Cites] Nat Genet. 2002 Nov;32(3):384-92 [12368912.001]
  • [Cites] J Gen Physiol. 1984 Nov;84(5):789-803 [6439817.001]
  • [Cites] J Membr Biol. 1985;88(1):1-13 [3937898.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jul 22;94(15):8202-7 [9223339.001]
  • [Cites] Am J Physiol. 1999 Mar;276(3 Pt 2):F359-66 [10070159.001]
  • [Cites] Biochem J. 1999 Apr 15;339 ( Pt 2):269-79 [10191257.001]
  • [Cites] Biochem Cell Biol. 1998;76(5):743-9 [10353707.001]
  • [Cites] J Clin Invest. 1999 Jun;103(11):1527-37 [10359562.001]
  • [Cites] Biochemistry. 1999 Jun 29;38(26):8521-31 [10387099.001]
  • [Cites] Am J Physiol. 1999 Nov;277(5 Pt 1):C899-912 [10564083.001]
  • [Cites] J Gen Physiol. 1999 Dec;114(6):743-58 [10578012.001]
  • [Cites] Biochemistry. 2000 Apr 4;39(13):3718-24 [10736171.001]
  • [Cites] J Biol Chem. 2000 Oct 13;275(41):32027-36 [10871601.001]
  • [Cites] Biochemistry. 2000 Nov 14;39(45):13838-47 [11076524.001]
  • [Cites] Cell Physiol Biochem. 2000;10(5-6):341-54 [11125215.001]
  • [Cites] Neuron. 2001 May;30(2):515-24 [11395011.001]
  • [Cites] Biochemistry. 2001 Sep 4;40(35):10700-6 [11524016.001]
  • [Cites] J Biol Chem. 2001 Nov 9;276(45):41870-8 [11551954.001]
  • [Cites] Biochem J. 1999 Aug 15;342 ( Pt 1):119-23 [10432308.001]
  • [Cites] Physiol Rev. 2005 Apr;85(2):423-93 [15788703.001]
  • [Cites] Biochem Cell Biol. 2006 Dec;84(6):1034-44 [17215889.001]
  • [Cites] J Clin Invest. 2007 Jun;117(6):1708-17 [17510708.001]
  • [Cites] J Biol Chem. 2007 Jun 22;282(25):18083-93 [17462999.001]
  • [Cites] Br J Haematol. 2008 Jan;140(1):80-5 [17991298.001]
  • [Cites] Biochem J. 2008 Jan 15;409(2):321-31 [18092945.001]
  • [Cites] Annu Rev Physiol. 2008;70:329-55 [17961084.001]
  • [Cites] J Cell Sci. 2008 Oct 15;121(Pt 20):3293-304 [18843116.001]
  • [Cites] Nature. 2002 Apr 25;416(6883):874-8 [11976689.001]
  • (PMID = 19380103.001).
  • [ISSN] 1096-0961
  • [Journal-full-title] Blood cells, molecules & diseases
  • [ISO-abbreviation] Blood Cells Mol. Dis.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R21 DK061051-02; United States / NIDDK NIH HHS / DK / DK61051; United States / NIDDK NIH HHS / DK / DK061051-02; United States / NHLBI NIH HHS / HL / R01 HL077765-01A2; United States / NHLBI NIH HHS / HL / HL15157
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cross-Linking Reagents; 0 / RNA, Complementary; 0 / Recombinant Fusion Proteins; 0 / Rubidium Radioisotopes; 0 / Symporters; 0 / potassium-chloride symporters
  • [Other-IDs] NLM/ NIHMS104896; NLM/ PMC2797447
  •  go-up   go-down


65. Barde C, Masouyé I, Saurat JH, Le Gal FA: [Scleroedema adultorum Buschke in a diabetic subject: intravenous immunoglobulin therapy]. Ann Dermatol Venereol; 2009 Apr;136(4):360-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Scléroedème de Buschke chez un diabétique: traitement par immunoglobulines intraveineuses.
  • BACKGROUND: Scleroedema adultorum Buschke (SB) is a rare disease involving scleroedema of the neck and shoulders.
  • Three types of SB are distinguished: the first is acute and develops after an infectious disease, the second is of insidious evolution and is associated with monoclonal gammopathy, and the third is associated with type 2 diabetes.
  • PATIENTS AND METHODS: We report the case of a type 2 diabetic patient presenting with progressive, oedematous timbering of the trunk associated with impaired mobility, dysphagia and restrictive respiratory syndrome.
  • Treatment was mandatory because of the adverse impact of the disease.

  • MedlinePlus Health Information. consumer health - Diabetes Type 2.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19361705.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Immunoglobulins, Intravenous
  •  go-up   go-down


66. Amrani Hassani M, Filali Baba A, Alami M, Lahlou H: [Laboratory diagnostic and prognostic factors: Multiple myeloma in Morocco]. Sante; 2010 Oct-Dec;20(4):209-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • ObjectivesThe purpose of this retrospective study was to clarify the factors for a laboratory diagnosis of multiple myeloma (Kahler's disease) and assess their prognostic value.MethodsThe study of all 10 patients with multiple myeloma seen during 2009 in the department of internal medicine and the haematology laboratory of HASSAN II University Hospital Centre in Fez.
  • The median concentration of the monoclonal component was 28 g/l.
  • Protein electrophoresis and myelography results are major diagnostic elements, because they make it possible to rule out a monoclonal gammopathy of undetermined significance, for which treatment differs completely from that for multiple myeloma.
  • [MeSH-major] Monoclonal Gammopathy of Undetermined Significance. Multiple Myeloma

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21320814.001).
  • [ISSN] 1157-5999
  • [Journal-full-title] Santé (Montrouge, France)
  • [ISO-abbreviation] Sante
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


67. Stojkovic T: [Neuropathy, monoclonal gammopathy and autoantibodies: how to establish a link?]. Rev Neurol (Paris); 2007 Sep;163 Spec No 1:3S45-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neuropathy, monoclonal gammopathy and autoantibodies: how to establish a link?].
  • [Transliterated title] Neuropathie, gammapathie monoclonale et auto-anticorps: comment établir un lien?
  • Monoclonal gammopathies are frequently observed in subjects older than 50 years.
  • Understanding the pathogenetic role of paraproteins in peripheral nervous system damage is a necessary step to establish a link between the monoclonal gammopathy and neuropathy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18087229.001).
  • [ISSN] 0035-3787
  • [Journal-full-title] Revue neurologique
  • [ISO-abbreviation] Rev. Neurol. (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Immunoglobulins
  • [Number-of-references] 41
  •  go-up   go-down


68. Kriangkum J, Taylor BJ, Reiman T, Belch AR, Pilarski LM: Origins of Waldenstrom's macroglobulinemia: does it arise from an unusual B-cell precursor? Clin Lymphoma; 2005 Mar;5(4):217-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Origins of Waldenstrom's macroglobulinemia: does it arise from an unusual B-cell precursor?
  • However, we found that the mutation of switch regions essential for CSR were present in IgM monoclonal gammopathy of unknown significance (MGUS) but absent from WM B cells, suggesting the possibility that not all IgM MGUS have the potential to give rise to WM, and further strengthening the hypothesis that the target cell in transformation to WM is an unusual type of B cell.
  • [MeSH-minor] Antigens, Bacterial. Cell Differentiation. Gene Rearrangement. Humans. Mutation. Paraproteinemias / immunology. Paraproteinemias / physiopathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15794851.001).
  • [ISSN] 1526-9655
  • [Journal-full-title] Clinical lymphoma
  • [ISO-abbreviation] Clin Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 80963
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Bacterial; 0 / Antigens, CD20; 0 / H antigen; 0 / Immunoglobulin M
  • [Number-of-references] 22
  •  go-up   go-down


69. Rajkumar SV: MGUS and smoldering multiple myeloma: update on pathogenesis, natural history, and management. Hematology Am Soc Hematol Educ Program; 2005;:340-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MGUS and smoldering multiple myeloma: update on pathogenesis, natural history, and management.
  • Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) are asymptomatic, pre-malignant disorders characterized by monoclonal plasma cell proliferation in the bone marrow and absence of end-organ damage.
  • Recent advances in the pathogenesis, natural history, and prognosis of MGUS and SMM are reviewed.
  • A new risk stratification system to determine the prognosis of MGUS using the size and type of M protein, and the serum free light chain assay is discussed.

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16304401.001).
  • [ISSN] 1520-4383
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA 107476; United States / NCI NIH HHS / CA / CA 62242
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glycoproteins; 0 / Immunoglobulin Heavy Chains; 0 / Myeloma Proteins; 0 / multiple myeloma M-proteins; 0 / protein M (glycoprotein)
  •  go-up   go-down


70. Fish R, Pinney J, Jain P, Addison C, Jones C, Jayawardene S, Booth J, Howie AJ, Ghonemy T, Rajabali S, Roberts D, White L, Khan S, Morgan M, Cockwell P, Hutchison CA: The incidence of major hemorrhagic complications after renal biopsies in patients with monoclonal gammopathies. Clin J Am Soc Nephrol; 2010 Nov;5(11):1977-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The incidence of major hemorrhagic complications after renal biopsies in patients with monoclonal gammopathies.
  • BACKGROUND AND OBJECTIVES: Monoclonal gammopathies frequently cause renal disease, but they may be an incidental finding.
  • Assessment of renal pathology in the context of renal dysfunction and a monoclonal gammopathy therefore serves as a useful diagnostic tool and, in addition, provides prognostic information.
  • The purpose of this study was to determine the incidence of significant hemorrhagic complications after renal biopsies in patients with monoclonal gammopathies.
  • Subjects were categorized as having a monoclonal gammopathy or not, and the incidence of major hemorrhagic complications between groups was compared.
  • One hundred forty-eight subjects with a monoclonal gammopathy were identified.
  • CONCLUSIONS: In the population studied, the rate of major hemorrhagic complications after percutaneous renal biopsy was not significantly greater in patients with a monoclonal gammopathy.
  • [MeSH-major] Hemorrhage / etiology. Kidney / pathology. Kidney Diseases / diagnosis. Paraproteinemias / complications

  • MedlinePlus Health Information. consumer health - Bleeding.
  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Soc Nephrol. 2001 Jul;12(7):1482-92 [11423577.001]
  • [Cites] Nephrol Dial Transplant. 2009 Aug;24(8):2433-9 [19246472.001]
  • [Cites] Curr Hematol Rep. 2003 Sep;2(5):388-94 [12932310.001]
  • [Cites] Arch Pathol Lab Med. 2004 Aug;128(8):875-9 [15270616.001]
  • [Cites] Kidney Int. 2004 Oct;66(4):1570-7 [15458453.001]
  • [Cites] Clin Nephrol. 1990 Dec;34(6):247-54 [2073767.001]
  • [Cites] Br J Haematol. 1995 Dec;91(4):854-9 [8547129.001]
  • [Cites] N Engl J Med. 1997 Sep 25;337(13):898-909 [9302305.001]
  • [Cites] Nephrol Dial Transplant. 1998 Apr;13(4):975-7 [9568860.001]
  • [Cites] Nephrol Dial Transplant. 1998 Jun;13(6):1438-45 [9641173.001]
  • [Cites] J Vasc Interv Radiol. 1998 Jul-Aug;9(4):651-5 [9684839.001]
  • [Cites] Clin Exp Nephrol. 2005 Mar;9(1):40-5 [15830272.001]
  • [Cites] Nephrology (Carlton). 2005 Jun;10(3):305-10 [15958047.001]
  • [Cites] Ann Intern Med. 2005 Dec 6;143(11):777-84 [16330788.001]
  • [Cites] Ann Intern Med. 2006 Aug 15;145(4):247-54 [16908915.001]
  • [Cites] Nephrol Dial Transplant. 2006 Dec;21(12):3601-2; author reply 3602 [17040998.001]
  • [Cites] Kidney Int. 2008 Jun;73(11):1282-8 [18385667.001]
  • [Cites] Kidney Int. 2008 Jun;73(11):1211-3 [18480853.001]
  • [Cites] BMC Nephrol. 2008;9:11 [18808676.001]
  • [Cites] Am J Kidney Dis. 2008 Dec;52(6):1079-83 [18649980.001]
  • [Cites] Artif Organs. 2008 Dec;32(12):910-7 [19133018.001]
  • [Cites] Clin J Am Soc Nephrol. 2009 Apr;4(4):745-54 [19339414.001]
  • [Cites] Br J Haematol. 2009 Apr;145(2):151-63 [19210509.001]
  • [Cites] Am J Kidney Dis. 2003 Jul;42(1):87-95 [12830460.001]
  • (PMID = 20651154.001).
  • [ISSN] 1555-905X
  • [Journal-full-title] Clinical journal of the American Society of Nephrology : CJASN
  • [ISO-abbreviation] Clin J Am Soc Nephrol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3001781
  •  go-up   go-down


71. Baughn LB, Di Liberto M, Niesvizky R, Cho HJ, Jayabalan D, Lane J, Liu F, Chen-Kiang S: CDK2 phosphorylation of Smad2 disrupts TGF-beta transcriptional regulation in resistant primary bone marrow myeloma cells. J Immunol; 2009 Feb 15;182(4):1810-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In multiple myeloma, a fatal cancer of plasma cells, malignant cells accumulate in the TGF-beta-rich bone marrow due to loss of both cell cycle and apoptotic controls.
  • Herein we show that TGF-beta activates Smad2 but fails to induce cell cycle arrest or apoptosis in primary bone marrow myeloma and human myeloma cell lines due to its inability to activate G(1) cyclin-dependent kinase (CDK) inhibitors (p15(INK4b), p21(CIP1/WAF1), p27(KIP1), p57(KIP2)) or to repress c-myc and Bcl-2 transcription.
  • Correlating with aberrant activation of CDKs, CDK-dependent phosphorylation of Smad2 on Thr(8) (pT8), a modification linked to impaired Smad activity, is elevated in primary bone marrow myeloma cells, even in asymptomatic monoclonal gammopathy of undetermined significance.
  • Our findings provide the first direct evidence that pT8 Smad2 couples dysregulation of CDK2 to TGF-beta resistance in primary cancer cells, and they suggest that disruption of Smad2 function by CDK2 phosphorylation acts as a mechanism for TGF-beta resistance in multiple myeloma.

  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19201832.001).
  • [ISSN] 1550-6606
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA120531; United States / NCI NIH HHS / CA / R01 CA93771
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / SMAD2 protein, human; 0 / Smad2 Protein; 0 / Transforming Growth Factor beta; EC 2.7.11.22 / CDK2 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 2
  •  go-up   go-down


72. Ramchandren S, Lewis RA: Monoclonal gammopathy and neuropathy. Curr Opin Neurol; 2009 Oct;22(5):480-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monoclonal gammopathy and neuropathy.
  • PURPOSE OF REVIEW: The management of peripheral neuropathy associated with monoclonal gammopathies has been advanced by recent clinical studies.
  • We review the causal association between monoclonal gammopathy and neuropathy, and critically review the recent evidence on treatment.
  • RECENT FINDINGS: IgM monoclonal gammopathy of undetermined significance (MGUS) is the most commonly found monoclonal gammopathy associated with neuropathy.
  • Neuropathies associated with specific lymphoproliferative disorders may not respond to treatments aimed at that disorder.
  • Standard immunomodulatory agents including steroids, intravenous immunoglobulin, and plasmapheresis have shown limited efficacy in IgM monoclonal gammopathy of undetermined significance.
  • Newer studies have shown promising results with rituximab, a monoclonal antibody which targets the B cell surface antigen CD20 and results in a rapid and sustained depletion of B cells.
  • SUMMARY: There is a clear association between peripheral neuropathy and IgM MGUS with characteristic clinical, electrophysiology and pathologic features that make the disorder distinct from chronic inflammatory demyelinating polyneuropathy.
  • The IgG and IgA monoclonal gammopathies are rarely associated with specific neuropathies.
  • Long-term studies looking at the association between specific immunologic markers and disease recurrence are needed to ultimately develop targeted therapies.

  • MedlinePlus Health Information. consumer health - Peripheral Nerve Disorders.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19625962.001).
  • [ISSN] 1473-6551
  • [Journal-full-title] Current opinion in neurology
  • [ISO-abbreviation] Curr. Opin. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 57
  •  go-up   go-down


73. Kawagashira Y, Kondo N, Atsuta N, Iijima M, Koike H, Katsuno M, Tanaka F, Kusunoki S, Sobue G: IgM MGUS anti-MAG neuropathy with predominant muscle weakness and extensive muscle atrophy. Muscle Nerve; 2010 Sep;42(3):433-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IgM MGUS anti-MAG neuropathy with predominant muscle weakness and extensive muscle atrophy.
  • We report a patient with anti-myelin-associated glycoprotein (MAG) neuropathy, predominantly exhibiting severe motor symptoms, accompanied by extensive muscle atrophy mimicking Charcot-Marie-Tooth disease.
  • [MeSH-minor] Charcot-Marie-Tooth Disease / pathology. Diagnosis, Differential. Electrodiagnosis. Humans. Immunoglobulins, Intravenous / therapeutic use. Lower Extremity / pathology. Male. Middle Aged. Muscular Atrophy. Neural Conduction / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20665518.001).
  • [ISSN] 1097-4598
  • [Journal-full-title] Muscle & nerve
  • [ISO-abbreviation] Muscle Nerve
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin M; 0 / Immunoglobulins, Intravenous; 0 / Myelin-Associated Glycoprotein
  •  go-up   go-down


74. Choi JH, Jo YJ, Gong SJ, Hong BW, Lee HJ, Son BK, Jun DW, Kim SH, Park YS, Seok JW: Unicentric castleman disease is not clearly distinguished from multicentric type: a case report. Clin Lymphoma Myeloma; 2008 Aug;8(4):256-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unicentric castleman disease is not clearly distinguished from multicentric type: a case report.
  • Castleman disease (CD) was recently classified as a unicentric hyaline vascular variant, unicentric plasma cell variant, and multicentric plasma cell variant.
  • The patient experienced anemia, weight loss, elevated C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes syndrome), and plasmacytosis in bone marrow without human herpesvirus-8 or HIV.
  • After exploratory laparotomy and lymphadenectomy under presumptive diagnosis of CD, the patient's symptoms recovered, and CRP and ESR decreased.
  • Therefore, we suggest that unicentric CD is not clearly distinguished from multicentric, the type in this report, focusing on the useful role of CRP, ESR, and positron emission tomography/computed tomography in the disease activity of CD.
  • [MeSH-major] Giant Lymph Node Hyperplasia / diagnosis. Giant Lymph Node Hyperplasia / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18765316.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9007-41-4 / C-Reactive Protein
  •  go-up   go-down


75. Hanamura I, Stewart JP, Huang Y, Zhan F, Santra M, Sawyer JR, Hollmig K, Zangarri M, Pineda-Roman M, van Rhee F, Cavallo F, Burington B, Crowley J, Tricot G, Barlogie B, Shaughnessy JD Jr: Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood; 2006 Sep 1;108(5):1724-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation.
  • Using fluorescence in situ hybridization we investigated amplification of chromosome band 1q21 (Amp1q21) in more than 500 untreated patients with monoclonal gammopathy of undetermined significance (MGUS; n = 14), smoldering multiple myeloma (SMM; n = 31), and newly diagnosed MM (n = 479) as well as 45 with relapsed MM.
  • The frequency of Amp1q21 was 0% in MGUS, 45% in SMM, 43% in newly diagnosed MM, and 72% in relapsed MM (newly diagnosed versus relapsed MM, P < .001).
  • Amp1q21 was detected in 10 of 12 patients whose disease evolved to active MM compared with 4 of 19 who remained with SMM (P < .001).
  • Patients with newly diagnosed MM with Amp1q21 had inferior 5-year event-free/overall survival compared with those lacking Amp1q21 (38%/52% versus 62%/78%, both P < .001).
  • The proportion of cells with Amp1q21 and the copy number of 1q21 tended to increase at relapse compared with diagnosis.
  • Our data suggest that Amp1q21 is associated with both disease progression and poor prognosis.

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jan 4;97(1):309-14 [10618414.001]
  • [Cites] Br J Cancer. 2000 Jan;82(1):65-73 [10638968.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Mar;117(2):89-96 [10704676.001]
  • [Cites] Blood. 2000 Apr 15;95(8):2666-71 [10753849.001]
  • [Cites] Blood. 2000 May 1;95(9):2930-6 [10779441.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6757-62 [10829078.001]
  • [Cites] Blood. 1994 Oct 1;84(7):2283-90 [7919347.001]
  • [Cites] Blood. 1995 Feb 1;85(3):650-6 [7833468.001]
  • [Cites] Genomics. 1994 Sep 15;23(2):457-63 [7835896.001]
  • [Cites] Cancer Res. 1995 Sep 1;55(17):3854-9 [7641204.001]
  • [Cites] Leukemia. 1995 Dec;9(12):2109-14 [8609724.001]
  • [Cites] Genes Chromosomes Cancer. 1997 Jun;19(2):124-33 [9172003.001]
  • [Cites] Blood. 1997 Nov 1;90(9):3682-90 [9345053.001]
  • [Cites] Blood. 1998 Mar 1;91(5):1732-41 [9473240.001]
  • [Cites] Blood. 1998 Mar 15;91(6):1873-81 [9490669.001]
  • [Cites] Blood. 1998 Apr 15;91(8):3007-10 [9531613.001]
  • [Cites] Blood. 1998 Sep 1;92(5):1743-8 [9716604.001]
  • [Cites] Nature. 1998 Dec 17;396(6712):643-9 [9872311.001]
  • [Cites] Int J Cancer. 1999 Apr 20;84(2):114-21 [10096241.001]
  • [Cites] Oncogene. 1999 Mar 25;18(12):2085-90 [10321732.001]
  • [Cites] Cancer Res. 1999 Sep 15;59(18):4546-50 [10493504.001]
  • [Cites] Am J Pathol. 2004 Jul;165(1):71-81 [15215163.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2661-6 [15238415.001]
  • [Cites] Clin Cancer Res. 1999 Sep;5(9):2526-31 [10499629.001]
  • [Cites] Nat Med. 2004 Nov;10(11):1251-6 [15502842.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Jan;42(1):78-81 [15390182.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Jan;42(1):95-106 [15472896.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Oct;44(2):194-203 [16001433.001]
  • [Cites] Br J Haematol. 2005 Sep;130(5):729-32 [16115129.001]
  • [Cites] Blood. 2006 Jan 1;107(1):397-403 [16144800.001]
  • [Cites] J Clin Oncol. 2006 Feb 20;24(6):929-36 [16432076.001]
  • [Cites] N Engl J Med. 2006 Mar 9;354(10):1021-30 [16525139.001]
  • [Cites] Blood. 2006 Apr 1;107(7):2633-8 [16322468.001]
  • [Cites] Cancer Cell. 2006 Apr;9(4):313-25 [16616336.001]
  • [Cites] Blood. 2000 Aug 15;96(4):1505-11 [10942398.001]
  • [Cites] Immunity. 2001 Mar;14(3):277-89 [11290337.001]
  • [Cites] Leukemia. 2001 May;15(5):840-5 [11368447.001]
  • [Cites] Blood. 2001 Oct 1;98(7):2229-38 [11568011.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Nov;32(3):250-64 [11579465.001]
  • [Cites] Oncogene. 2001 Nov 15;20(52):7686-93 [11753646.001]
  • [Cites] Blood. 2002 Mar 1;99(5):1745-57 [11861292.001]
  • [Cites] Nat Rev Cancer. 2002 Mar;2(3):175-87 [11990854.001]
  • [Cites] Blood. 2002 Aug 15;100(4):1417-24 [12149226.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Dec;35(4):318-28 [12378526.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4569-75 [12576322.001]
  • [Cites] Immunol Rev. 2003 Aug;194:112-39 [12846812.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2535-7 [14523465.001]
  • [Cites] Blood. 2004 Jan 1;103(1):20-32 [12969978.001]
  • [Cites] N Engl J Med. 2003 Dec 25;349(26):2495-502 [14695409.001]
  • (PMID = 16705089.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA55819; United States / NCI NIH HHS / CA / CA97513
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1895503
  •  go-up   go-down


76. Hoffman-Snyder C, Smith BE: Neuromuscular disorders associated with paraproteinemia. Phys Med Rehabil Clin N Am; 2008 Feb;19(1):61-79, vi
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neuromuscular disorders associated with monoclonal gammopathies are usually uncovered in approximately 10% of patients presenting with peripheral neuropathy complaints.
  • This discovery should prompt further evaluation for underlying plasma cell dyscrasias.
  • The most frequent monoclonal disorders associated with neuropathy are smoldering myeloma, multiple myeloma, Waldenström macroglobulinemia, solitary plasmacytoma, systemic immunoglobulin light chain (AL) amyloidosis, POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes), and cryoglobulinemia.
  • If these are excluded by careful evaluation the patient is classified as having monoclonal gammopathy of undetermined significance.

  • MedlinePlus Health Information. consumer health - Neuromuscular Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18194750.001).
  • [ISSN] 1047-9651
  • [Journal-full-title] Physical medicine and rehabilitation clinics of North America
  • [ISO-abbreviation] Phys Med Rehabil Clin N Am
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 40
  •  go-up   go-down


77. Ashawesh K, Fiad TM: Spontaneous recovery of adrenal insufficiency in POEMS syndrome. Medscape J Med; 2009;11(1):21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • POEMS syndrome is a rare multisystem disorder characterized by polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes.
  • We report the first case of spontaneous recovery of adrenal insufficiency in a patient with POEMS syndrome treated with autologous hematopoietic cell transplantation.
  • [MeSH-major] Adrenal Insufficiency / diagnosis. Adrenal Insufficiency / surgery. POEMS Syndrome / diagnosis. POEMS Syndrome / surgery
  • [MeSH-minor] Adult. Female. Hematopoietic Stem Cell Transplantation / methods. Humans. Remission Induction / methods. Treatment Outcome

  • Genetic Alliance. consumer health - POEMS syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1988;413(4):357-65 [2845640.001]
  • [Cites] Mayo Clin Proc. 2007 Jul;82(7):836-42 [17605964.001]
  • [Cites] Am J Med. 1994 Dec;97(6):543-53 [7985714.001]
  • (PMID = 19295942.001).
  • [ISSN] 1934-1997
  • [Journal-full-title] Medscape journal of medicine
  • [ISO-abbreviation] Medscape J Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2654695
  •  go-up   go-down


78. Imai N, Kitamura E, Tachibana T, Konishi T, Suzuki Y, Serizawa M, Okabe T, Fujita H: Efficacy of autologous peripheral blood stem cell transplantation in POEMS syndrome with polyneuropathy. Intern Med; 2007;46(3):135-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of autologous peripheral blood stem cell transplantation in POEMS syndrome with polyneuropathy.
  • POEMS syndrome (POEMS) is a rare multi-system disease which is typically associated with polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin changes.
  • We report herein a case of POEMS with progressive polyneuropathy resistant to high-dose intravenous immunoglobulin therapy who experienced improvement in polyneuropathy after the administration of high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation.
  • Improvements in polyneuropathy remain despite recognition of monoclonal gammopathy by immunofixation as of 1 year after treatment.
  • We demonstrated that autologous peripheral blood stem cell transplantation can improve clinical symptoms and signs due to polyneuropathy in POEMS even without achieving complete remission.
  • [MeSH-major] POEMS Syndrome / therapy. Peripheral Blood Stem Cell Transplantation

  • Genetic Alliance. consumer health - POEMS syndrome.
  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17268130.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


79. Berenson JR, Yellin O: Monoclonal gammopathy of undetermined significance: why identification of these patients and assessment of their skeletons is important. Clin Lymphoma Myeloma; 2009 Aug;9(4):311-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monoclonal gammopathy of undetermined significance: why identification of these patients and assessment of their skeletons is important.
  • Monoclonal gammopathy of undetermined significance (MGUS) is a plasma cell disorder characterized by the presence of a serum monoclonal immunoglobulin (M-protein) at <or= 3 g/dL.
  • It is an asymptomatic premalignant disorder that can progress to multiple myeloma and related B-cell disorders.
  • Recent studies have suggested the association of MGUS with enhanced bone loss and debilitating skeletal complications, particularly vertebral compression fractures (VCFs) often leading to back pain.
  • Early identification of MGUS and evaluation of bone status will facilitate prophylactic treatment with bisphosphonates to increase bone density and likely reduce the risk of fractures as well as identify patients with VCFs who might benefit from early surgical intervention.
  • [MeSH-major] Fractures, Compression / diagnosis. Fractures, Compression / therapy. Monoclonal Gammopathy of Undetermined Significance / diagnosis. Monoclonal Gammopathy of Undetermined Significance / therapy. Multiple Myeloma / diagnosis. Multiple Myeloma / therapy
  • [MeSH-minor] Antibodies, Monoclonal / blood. Humans. Quality of Life. Risk Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19717382.001).
  • [ISSN] 1938-0712
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal
  •  go-up   go-down


80. Vital A, Nedelec-Ciceri C, Vital C: Presence of crystalline inclusions in the peripheral nerve of a patient with IgA lambda monoclonal gammopathy of undetermined significance. Neuropathology; 2008 Oct;28(5):526-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Presence of crystalline inclusions in the peripheral nerve of a patient with IgA lambda monoclonal gammopathy of undetermined significance.
  • Association of a peripheral neuropathy with an IgA monoclonal gammopathy of undetermined significance (MGUS) is not commonly observed and is sometimes considered as coincidental.
  • We present a case in which the nerve biopsy revealed the presence of crystalline inclusions in the endoneurium, a very unusual finding.
  • An IgA lambda MGUS was evidenced in his serum at 10.2 g/L with 7% plasma cells in his bone marrow and no lytic lesion at skeletal examination.
  • Such crystalline inclusions have mainly been observed in the cytoplasm of plasma cells in cases of multiple myeloma, and correspond to non-secreted IgA or IgG immunoglobulins with a kappa or rarely lambda light chain.
  • Such inclusions have also been reported in the cytoplasm of the epithelial cells from corneal fragments, in patients with multiple myeloma or IgG MGUS, and in the tubular cells from the kidney of patients with multiple myeloma and a nephrotic syndrome.

  • MedlinePlus Health Information. consumer health - Peripheral Nerve Disorders.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18410274.001).
  • [ISSN] 1440-1789
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Immunoglobulin A; 0 / Immunoglobulin lambda-Chains
  •  go-up   go-down


81. Blotta S, Tassone P, Prabhala RH, Tagliaferri P, Cervi D, Amin S, Jakubikova J, Tai YT, Podar K, Mitsiades CS, Zullo A, Franco B, Anderson KC, Munshi NC: Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance. Blood; 2009 Oct 08;114(15):3276-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance.
  • The transformation from monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma (MM) is thought to be associated with changes in immune processes.
  • We have therefore used serologic analysis of recombinant cDNA expression library to screen the sera of MGUS patients to identify tumor-associated antigens.
  • A total of 10 antigens were identified, with specific antibody responses in MGUS.
  • Importantly, the gene responsible for the oral-facial-digital type I syndrome (OFD1) had response in 6 of 29 (20.6%) MGUS patients but 0 of 11 newly diagnosed MM patients.
  • Interestingly, 3 of 11 (27.2%) MM patients after autologous stem cell transplantations showed responses to OFD1.
  • We have confirmed T-cell responses against OFD1 in MGUS and observed down-regulation of GLI1/PTCH1 and p-beta-catenin after OFD1 knock-down with specific siRNA, suggesting its functional role in the regulation of Hh and Wnt pathways.
  • These findings demonstrate OFD1 as an important immune target and highlight its possible role in signal transduction and tumorigenesis in MGUS and MM.
  • [MeSH-minor] Aged. Aged, 80 and over. Apoptosis Regulatory Proteins / genetics. Apoptosis Regulatory Proteins / immunology. Carrier Proteins / genetics. Carrier Proteins / immunology. DNA, Complementary / genetics. Female. Humans. Male. Nuclear Proteins / genetics. Nuclear Proteins / immunology. Patched Receptors. Patched-1 Receptor. RNA-Binding Proteins / genetics. RNA-Binding Proteins / immunology. Receptors, Cell Surface / genetics. Receptors, Cell Surface / immunology. Signal Transduction / immunology. Stem Cell Transplantation. T-Lymphocytes / immunology. Transplantation, Autologous. beta Catenin / genetics. beta Catenin / immunology

  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Aug;18(16):3031-7 [10944138.001]
  • [Cites] Br J Haematol. 2008 Feb;140(4):465-8 [18217892.001]
  • [Cites] N Engl J Med. 2002 Feb 21;346(8):564-9 [11856795.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2210-6 [12114422.001]
  • [Cites] Blood. 2002 Aug 15;100(4):1417-24 [12149226.001]
  • [Cites] Br J Haematol. 2003 Jan;120(1):3-9 [12492570.001]
  • [Cites] Int J Cancer. 2003 Mar 10;104(1):73-84 [12532422.001]
  • [Cites] Blood. 2003 Mar 15;101(6):2377-80 [12424198.001]
  • [Cites] Cancer Immun. 2001 Mar 30;1:4 [12747765.001]
  • [Cites] N Engl J Med. 2003 Jun 26;348(26):2609-17 [12826635.001]
  • [Cites] J Exp Med. 2003 Dec 1;198(11):1753-7 [14638846.001]
  • [Cites] Blood. 2004 Jan 15;103(2):656-63 [14563636.001]
  • [Cites] Cancer Immun. 2004 Jul 16;4:5 [15255672.001]
  • [Cites] J Am Soc Nephrol. 2004 Oct;15(10):2556-68 [15466260.001]
  • [Cites] J Biol Regul Homeost Agents. 2004 Apr-Jun;18(2):161-5 [15471221.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11810-3 [8524854.001]
  • [Cites] Pathobiology. 1995;63(4):222-38 [8866794.001]
  • [Cites] Cell Biol Int. 1996 Jan;20(1):73-81 [8936410.001]
  • [Cites] Int J Cancer. 1998 May 29;76(5):652-8 [9610721.001]
  • [Cites] Cancer Res. 1999 Sep 15;59(18):4546-50 [10493504.001]
  • [Cites] Blood. 1999 Oct 15;94(8):2583-9 [10515861.001]
  • [Cites] Leukemia. 2005 Mar;19(3):449-55 [15674420.001]
  • [Cites] Blood. 2005 Jun 1;105(11):4532-9 [15731182.001]
  • [Cites] Int J Cancer. 2005 Sep 20;116(5):813-9 [15849745.001]
  • [Cites] Gynecol Oncol. 2005 Oct;99(1):183-8 [16005946.001]
  • [Cites] Nat Genet. 2006 Jan;38(1):112-7 [16311594.001]
  • [Cites] N Engl J Med. 2006 Mar 30;354(13):1362-9 [16571879.001]
  • [Cites] Cancer Res. 2006 Jul 1;66(13):6463-7 [16818613.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Jan 29;105(4):1285-90 [18202175.001]
  • [Cites] Blood. 2008 Mar 1;111(5):2516-20 [17975015.001]
  • [Cites] Cancer Res. 2008 Apr 1;68(7):2058-61 [18381407.001]
  • [Cites] Mod Pathol. 2008 May;21(5):505-16 [18277965.001]
  • [Cites] Hum Mutat. 2008 Oct;29(10):1237-46 [18546297.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Nov 4;105(44):17103-8 [18952841.001]
  • [Cites] Nat Rev Immunol. 2008 Dec;8(12):970-6 [19008897.001]
  • [Cites] Hum Mol Genet. 2009 Jan 15;18(2):289-303 [18971206.001]
  • [Cites] Science. 2006 Aug 4;313(5787):629-33 [16888132.001]
  • [Cites] Blood. 2006 Sep 1;108(5):1724-32 [16705089.001]
  • [Cites] Clin Cancer Res. 2006 Oct 1;12(19):5887-94 [17020997.001]
  • [Cites] Traffic. 2007 Feb;8(2):97-109 [17241444.001]
  • [Cites] Blood. 2007 Feb 15;109(4):1692-700 [17023574.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3588-94 [17158231.001]
  • [Cites] J Exp Med. 2007 Apr 16;204(4):831-40 [17389240.001]
  • [Cites] Science. 2007 Jul 20;317(5836):330-1 [17641189.001]
  • [Cites] Br J Haematol. 2007 Sep;138(5):563-79 [17686051.001]
  • [Cites] Leukemia. 2007 Oct;21(10):2137-44 [17690704.001]
  • [Cites] Annu Rev Cell Dev Biol. 2007;23:345-73 [17506691.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Nov;8(11):880-93 [17955020.001]
  • [Cites] Mol Biol Cell. 2007 Nov;18(11):4397-404 [17761535.001]
  • [Cites] Nat Cell Biol. 2008 Jan;10(1):70-6 [18084282.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):3071-6 [11306489.001]
  • (PMID = 19587378.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United States / PHS HHS / / P01-78378; Italy / Telethon / / TGM06Z08; United States / NCI NIH HHS / CA / P50CA-100707; United States / NCI NIH HHS / CA / P01 CA078378; United States / PHS HHS / / R01-129494; United States / NCI NIH HHS / CA / P01 CA155258; United States / NCI NIH HHS / CA / P50 CA100707
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Autoantigens; 0 / Carrier Proteins; 0 / DNA, Complementary; 0 / IRF2BP2 protein, human; 0 / Nuclear Proteins; 0 / OFD1 protein, human; 0 / PTCH protein, human; 0 / Patched Receptors; 0 / Patched-1 Receptor; 0 / Proteins; 0 / RNA-Binding Proteins; 0 / Receptors, Cell Surface; 0 / beta Catenin
  • [Other-IDs] NLM/ PMC2759650
  •  go-up   go-down


82. Schröder R, Deckert M, Linke RP: Novel isolated cerebral ALlambda amyloid angiopathy with widespread subcortical distribution and leukoencephalopathy due to atypical monoclonal plasma cell proliferation, and terminal systemic gammopathy. J Neuropathol Exp Neurol; 2009 Mar;68(3):286-99
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel isolated cerebral ALlambda amyloid angiopathy with widespread subcortical distribution and leukoencephalopathy due to atypical monoclonal plasma cell proliferation, and terminal systemic gammopathy.
  • Neuropathologic and biochemical findings in a 34-year-old man whose disease began 2 years before death appearing as chronic progressive encephalitis and culminated in mutism are reported.
  • Cerebrospinal fluid and serum of the patient showed a brain-restricted monoclonal lambda-light chain apparently produced by a small monoclonal immunoglobulin Glambda plasma cell population.
  • In the preterminal stage, there was a systemic monoclonal gammopathy, the source of which could not be identified.
  • At autopsy, there was extensive amyloid deposition in most vessels throughout the cerebral and cerebellar white matter, basal ganglia, and thalamus and diffuse leukoencephalopathy; cerebral and cerebellar cortices, other portions of the CNS, and non-CNS tissues were spared.
  • Partial amino acid sequence analysis demonstrated that the amyloidogenic protein originated from immunoglobulin lambda-light chains which were produced by monoclonal plasma cells.
  • [MeSH-major] Amyloid / metabolism. Cerebral Amyloid Angiopathy / pathology. Dementia, Vascular / pathology. Paraproteinemias / pathology. Plasma Cells / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19225408.001).
  • [ISSN] 0022-3069
  • [Journal-full-title] Journal of neuropathology and experimental neurology
  • [ISO-abbreviation] J. Neuropathol. Exp. Neurol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amyloid; 0 / Immunoglobulin lambda-Chains; 0 / amyloid protein AL
  •  go-up   go-down


83. Tsai DE, Aqui NA, Tomaszewski JE, Olthoff KM, Ahya VN, Kotloff RM, Bloom RD, Brozena SC, Hodinka RL, Stadtmauer EA, Schuster SJ, Nasta SD, Porter DL, Luger SM, Klumpp TR: Serum protein electrophoresis abnormalities in adult solid organ transplant patients with post-transplant lymphoproliferative disorder. Clin Transplant; 2005 Oct;19(5):644-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum protein electrophoresis abnormalities in adult solid organ transplant patients with post-transplant lymphoproliferative disorder.
  • Post-transplant lymphoproliferative disorder (PTLD) is an Epstein-Barr virus (EBV) associated malignancy that occurs in the setting of pharmacologic immunosuppression used after organ transplantation.
  • The presence of monoclonal gammopathy (MG) after organ transplantation is a risk factor for the development of PTLD.
  • Background gammaglobulin levels were abnormal in 13 (34%) patients with five (13%) and eight (21%) having polyclonal hypergammaglobulinemia or hypogammaglobulinemia, respectively.
  • Hypogammaglobulinemia was correlated with the presence of MG (p = 0.01) and polymorphic B-cell hyperplasia histology (p = 0.01).

  • MedlinePlus Health Information. consumer health - Organ Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16146557.001).
  • [ISSN] 0902-0063
  • [Journal-full-title] Clinical transplantation
  • [ISO-abbreviation] Clin Transplant
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Blood Proteins; 0 / Immunosuppressive Agents
  •  go-up   go-down


84. Gregorek H, Chrzanowska KH, Dzierzanowska-Fangrat K, Wakulińska A, Pietrucha B, Zapaśnik A, Zborowska M, Pac M, Smółka-Afifi D, Kasztelewicz B, Piekutowska-Abramczuk D, Małdyk J: Nijmegen breakage syndrome: Long-term monitoring of viral and immunological biomarkers in peripheral blood before development of malignancy. Clin Immunol; 2010 Jun;135(3):440-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Selected viruses and immune parameters were monitored in 57 patients with Nijmegen breakage syndrome as a proposed tool for early detection of changes preceding development of malignancy.
  • (2) monoclonal proteins; and (3) B-cell and T-cell receptor gene rearrangements in peripheral blood lymphocytes.
  • Monoclonal gammopathy detected in 38.6% of cases correlated with the presence of EBV DNA (p=0.002) and HCV RNA (p=0.04).
  • Systematic PCR analysis for viral infections and Ig/TCR gene rearrangements, supplemented by detection of monoclonal proteins, is advantageous in monitoring NBS patients before severe complications of the disease, including cancer, appear.
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Gene Rearrangement, B-Lymphocyte. Gene Rearrangement, T-Lymphocyte. Humans. Infant. Male. Paraproteinemias. Receptors, Antigen, B-Cell / genetics. Receptors, Antigen, T-Cell / genetics. Reverse Transcriptase Polymerase Chain Reaction. T-Lymphocyte Subsets / immunology. Young Adult

  • Genetic Alliance. consumer health - Nijmegen breakage syndrome.
  • MedlinePlus Health Information. consumer health - Viral Infections.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20167538.001).
  • [ISSN] 1521-7035
  • [Journal-full-title] Clinical immunology (Orlando, Fla.)
  • [ISO-abbreviation] Clin. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Antigen, B-Cell; 0 / Receptors, Antigen, T-Cell
  •  go-up   go-down


85. Corre J, Mahtouk K, Attal M, Gadelorge M, Huynh A, Fleury-Cappellesso S, Danho C, Laharrague P, Klein B, Rème T, Bourin P: Bone marrow mesenchymal stem cells are abnormal in multiple myeloma. Leukemia; 2007 May;21(5):1079-88
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To address this hypothesis in multiple myeloma (MM), we studied bone marrow mesenchymal stem cells (BMMSCs), the only long-lived cells of the bone marrow microenvironment, by gene expression profiling and phenotypic and functional studies in three groups of individuals: patients with MM, patients with monoclonal gamopathy of undefined significance (MGUS) and healthy age-matched subjects.
  • MGUS BMMSCs were interspersed between these two groups.
  • In particular, GDF15 was found to induce dose-dependent growth of MOLP-6, a stromal cell-dependent myeloma cell line.
  • [MeSH-minor] Adult. Aged. Cell Differentiation. Cell Proliferation. Cytokines / genetics. Female. Gene Expression Profiling. Growth Differentiation Factor 15. Hematopoiesis. Humans. Male. Middle Aged. Osteoblasts / cytology

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 21;97(24):13384-9 [11087877.001]
  • [Cites] Blood. 2000 Sep 1;96(5):1953-60 [10961900.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Dec;85(12):4781-8 [11134143.001]
  • [Cites] Endocrinology. 2001 Mar;142(3):1098-106 [11181524.001]
  • [Cites] Cancer. 2001 Apr 1;91(7):1219-30 [11283920.001]
  • [Cites] J Biol Chem. 2001 May 4;276(18):14728-36 [11278272.001]
  • [Cites] Nature. 2001 May 17;411(6835):375-9 [11357145.001]
  • [Cites] Leukemia. 2001 Dec;15(12):1950-61 [11753617.001]
  • [Cites] J Immunol. 2002 Jul 15;169(2):642-6 [12097364.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2578-85 [12239172.001]
  • [Cites] Endocrinology. 2002 Dec;143(12):4755-63 [12446603.001]
  • [Cites] Bioinformatics. 2002 Dec;18(12):1593-9 [12490443.001]
  • [Cites] Br J Haematol. 2003 Jan;120(1):10-7 [12492571.001]
  • [Cites] J Biol Chem. 2003 Mar 14;278(11):8904-12 [12514175.001]
  • [Cites] Am J Pathol. 2003 May;162(5):1521-8 [12707035.001]
  • [Cites] Br J Haematol. 2003 Jul;122(1):39-52 [12823344.001]
  • [Cites] Blood. 2003 Jul 15;102(2):592-600 [12663452.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2642-50 [12855642.001]
  • [Cites] J Biol Chem. 2003 Jul 25;278(30):28067-78 [12740383.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2003;:248-78 [14633785.001]
  • [Cites] N Engl J Med. 2003 Dec 25;349(26):2483-94 [14695408.001]
  • [Cites] N Engl J Med. 2003 Dec 25;349(26):2495-502 [14695409.001]
  • [Cites] J Cell Sci. 2004 Mar 15;117(Pt 8):1495-502 [14996910.001]
  • [Cites] Clin Cancer Res. 2004 Apr 1;10(7):2386-92 [15073115.001]
  • [Cites] Anal Biochem. 2004 Jun 1;329(1):77-84 [15136169.001]
  • [Cites] Br J Haematol. 2004 Aug;126(4):475-86 [15287939.001]
  • [Cites] Am J Pathol. 2004 Sep;165(3):855-67 [15331410.001]
  • [Cites] Oncogene. 2004 Sep 9;23(41):6986-90 [15286708.001]
  • [Cites] Cancer Cell. 2004 Jul;6(1):17-32 [15261139.001]
  • [Cites] Bone. 2004 Aug;35(2):517-24 [15268904.001]
  • [Cites] Blood. 1991 Jun 15;77(12):2688-93 [1675130.001]
  • [Cites] Mol Immunol. 1991 Nov;28(11):1183-92 [1720501.001]
  • [Cites] FEBS Lett. 1993 Nov 8;334(1):41-4 [8224224.001]
  • [Cites] Blood. 1993 Dec 15;82(12):3712-20 [8260708.001]
  • [Cites] Br J Haematol. 1993 Nov;85(3):446-51 [8136264.001]
  • [Cites] Blood. 1994 Jun 15;83(12):3654-63 [8204890.001]
  • [Cites] Leuk Res. 1994 Sep;18(9):675-82 [7934143.001]
  • [Cites] Blood. 1995 Feb 15;85(4):863-72 [7849308.001]
  • [Cites] N Engl J Med. 1996 Jul 11;335(2):91-7 [8649495.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] Blood. 1999 Jan 1;93(1):300-5 [9864174.001]
  • [Cites] Br J Haematol. 1998 Dec;103(4):1152-60 [9886334.001]
  • [Cites] Cell Tissue Res. 1999 Jul;297(1):103-10 [10398887.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 31;96(18):10278-83 [10468599.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):332-7 [15549095.001]
  • [Cites] Neoplasia. 2005 Jan;7(1):57-66 [15720817.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1700-9 [15753365.001]
  • [Cites] Hematology. 2004 Oct-Dec;9(5-6):377-81 [15763977.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2330-6 [15781647.001]
  • [Cites] Oncogene. 2005 May 12;24(21):3512-24 [15735670.001]
  • [Cites] Best Pract Res Clin Haematol. 2005;18(4):653-72 [16026743.001]
  • [Cites] Nat Genet. 2005 Aug;37(8):899-905 [16007089.001]
  • [Cites] Blood. 2005 Nov 1;106(9):3160-5 [16030194.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):2953-61 [16540643.001]
  • [Cites] Immunol Rev. 2006 Apr;210:86-104 [16623766.001]
  • [Cites] Stem Cells. 2006 Apr;24(4):986-91 [16293576.001]
  • [Cites] Hum Cell. 2000 Mar;13(1):43-54 [10937346.001]
  • [Cites] Br J Haematol. 2000 Nov;111(2):626-34 [11122111.001]
  • (PMID = 17344918.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytokines; 0 / GDF15 protein, human; 0 / Growth Differentiation Factor 15
  • [Other-IDs] NLM/ HALMS270565; NLM/ PMC2346535
  •  go-up   go-down


86. Nobile-Orazio E: Update on neuropathies associated with monoclonal gammopathy of undetermined significance (2008-2010). J Peripher Nerv Syst; 2010 Dec;15(4):302-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Update on neuropathies associated with monoclonal gammopathy of undetermined significance (2008-2010).
  • Studies on paraproteinemic neuropathies have appeared in the last 2 years improving the diagnosis of these neuropathies, clarifying their pathogenesis, and informing practice by randomized clinical trial publications.
  • [MeSH-major] Paraproteinemias / diagnosis. Paraproteinemias / therapy. Polyneuropathies / diagnosis. Polyneuropathies / therapy
  • [MeSH-minor] Animals. Antibodies, Monoclonal, Murine-Derived / therapeutic use. Humans. Randomized Controlled Trials as Topic / methods. Rituximab

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Peripheral Nerve Society.
  • (PMID = 21199101.001).
  • [ISSN] 1529-8027
  • [Journal-full-title] Journal of the peripheral nervous system : JPNS
  • [ISO-abbreviation] J. Peripher. Nerv. Syst.
  • [Language] eng
  • [Publication-type] Congresses
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


87. Flórez AF, Gallardo Agromayor E, García-Barredo R, Landeras Alvaro RM, Gorriño Angulo M, Martínez-Taboada VM, Fernández Echevarría MA: Radiological aid to clinical diagnosis of Schnitzler's syndrome: multimodality imaging approach. Clin Rheumatol; 2008 Jan;27(1):107-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiological aid to clinical diagnosis of Schnitzler's syndrome: multimodality imaging approach.
  • Schnitzler's syndrome is a rare combination of chronic urticaria, fever of unknown origin, disabling bone pain, and monoclonal gammopathy.
  • We report a case with an unusual radiological manifestation as a solitary sclerotic lesion of the right iliac bone.

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arthritis Rheum. 2005 Jul;52(7):2226-7 [15986356.001]
  • [Cites] Eur J Dermatol. 1998 Mar;8(2):118-21 [9649652.001]
  • [Cites] Br J Dermatol. 2006 Oct;155(4):827-9 [16965436.001]
  • [Cites] Radiology. 1993 Sep;188(3):669-73 [8351330.001]
  • [Cites] Mayo Clin Proc. 1995 Jun;70(6):570-2 [7776718.001]
  • [Cites] Radiology. 2001 Jul;220(1):225-30 [11426002.001]
  • [Cites] J Investig Allergol Clin Immunol. 1994 Jul-Aug;4(4):203-5 [7850035.001]
  • [Cites] Medicine (Baltimore). 2001 Jan;80(1):37-44 [11204501.001]
  • [Cites] Skeletal Radiol. 2007 Feb;36(2):153-6 [16602013.001]
  • [Cites] AJR Am J Roentgenol. 2000 Nov;175(5):1325-7 [11044033.001]
  • [Cites] Skeletal Radiol. 1998 May;27(5):294-6 [9638843.001]
  • [Cites] Semin Arthritis Rheum. 2007 Dec;37(3):137-48 [17586002.001]
  • (PMID = 17982708.001).
  • [ISSN] 0770-3198
  • [Journal-full-title] Clinical rheumatology
  • [ISO-abbreviation] Clin. Rheumatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antirheumatic Agents; 0 / Immunosuppressive Agents; 0 / Interleukin 1 Receptor Antagonist Protein; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


88. Treon SP, Hunter ZR, Aggarwal A, Ewen EP, Masota S, Lee C, Santos DD, Hatjiharissi E, Xu L, Leleu X, Tournilhac O, Patterson CJ, Manning R, Branagan AR, Morton CC: Characterization of familial Waldenstrom's macroglobulinemia. Ann Oncol; 2006 Mar;17(3):488-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Familial clustering of B-cell disorders among Waldenström's macroglobulinemia (WM) patients has been reported, though the frequency and any differences in disease manifestation for familial patients remain to be defined.
  • Forty-eight (18.7%) patients had at least one first-degree relative with either WM (n = 13, 5.1%), or another B-cell disorder including non-Hodgkin's lymphoma (n = 9, 3.5%), myeloma (n = 8, 3.1%), chronic lymphocytic leukemia (n = 7, 2.7%), monoclonal gammopathy of unknown significance (n = 5, 1.9%), acute lymphocytic leukemia (n = 3, 1.2%) and Hodgkin's disease (n = 3, 1.2%).
  • Patients with a familial history of WM or a plasma cell disorder (PCD) were diagnosed at a younger age and with greater bone marrow involvement.
  • RESULTS: Deletions in 6q represented the only recurrent structural chromosomal abnormality and were found in 13% of patients, all non-familial cases.
  • CONCLUSIONS: The above results suggest a high degree of clustering for B-cell disorders among first-degree relatives of patients with WM, along with distinct clinical features at presentation based on familial disease cluster patterns.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16357024.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K23 CA087977-03; United States / NCI NIH HHS / CA / P30 CA06516
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


89. Joint Task Force of the EFNS and the PNS: European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of paraproteinemic demyelinating neuropathies. Report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society--first revision. J Peripher Nerv Syst; 2010 Sep;15(3):185-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of paraproteinemic demyelinating neuropathies. Report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society--first revision.
  • (1) patients with PDN should be investigated for a malignant plasma cell dyscrasia;.
  • (2) a monoclonal gammopathy of undetermined significance is more likely to be causing the neuropathy if it is immunoglobulin (Ig)M, anti-neural antibodies are present, and the clinical phenotype is chronic distal sensory neuropathy;.
  • Their potential benefit should be balanced against possible side effects and the usually slow disease progression;.
  • (5) IgG and IgA PDN may be indistinguishable from chronic inflammatory demyelinating polyradiculoneuropathy; and (6) Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal gammopathy, and Skin changes syndrome is a multi-system malignant PDN.
  • [MeSH-major] Paraproteinemias / diagnosis. Paraproteinemias / therapy. Polyradiculoneuropathy / diagnosis. Polyradiculoneuropathy / therapy

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Peripheral Nerve Society.
  • (PMID = 21040140.001).
  • [ISSN] 1529-8027
  • [Journal-full-title] Journal of the peripheral nervous system : JPNS
  • [ISO-abbreviation] J. Peripher. Nerv. Syst.
  • [Language] eng
  • [Publication-type] Guideline; Journal Article
  • [Publication-country] United States
  • [Investigator] Hadden RD; Nobile-Orazio E; Sommer CL; Hahn AF; Illa I; Morra E; Pollard JD; Lunn MP; Bouche P; Cornblath DR; Evers E; Koski CL; Léger JM; Van den Bergh P; van Doorn PA; van Schaik IN
  •  go-up   go-down


90. Scudla V, Adam Z: [Diagnostic importance and pitfalls of evaluating bone marrow smear preparation in multiple myeloma]. Vnitr Lek; 2006 Nov;52 Suppl 2:55-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Special attention is given to the indication and technique of aspiration biopsy, diagnostic and differential-diagnostic importance of evaluating the percentage representation of plasmatic cells in the bone marrow and their morphological deviation from the point of view of distinguishing them from reactive plasmocytosis and monoclonal gammopathy of undetermined significance.
  • Also addressed is the issue of selected morphological classification systems including their benefits in identifying and forecasting the prognosis for the disease.
  • A large part of the report is dedicated to the interpretational limitations of evaluating BM smear samples for the diagnosis and monitoring of the course of MM, and due attention is also given to indication for and assessment of the importance of histological examination of a BM trepanobioptic sample of bone marrow and the benefits of particular specialized methods, especially the examination of immunophenotypic, proliferative and apoptotic qualities of plasmocytes.
  • [MeSH-minor] Biopsy, Needle. Bone Marrow Examination. Cytodiagnosis. Diagnosis, Differential. Humans

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18175430.001).
  • [ISSN] 0042-773X
  • [Journal-full-title] Vnitr̆ní lékar̆ství
  • [ISO-abbreviation] Vnitr Lek
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Czech Republic
  • [Number-of-references] 38
  •  go-up   go-down


91. Spier BJ, Einstein M, Johnson EA, Zuricik AO 3rd, Hu JL, Pfau PR: Amyloidosis presenting as lower gastrointestinal hemorrhage. WMJ; 2008 Feb;107(1):40-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AL-Amyloid rarely presents in the gastrointestinal tract as acute gastrointestinal hemorrhage, especially in the absence of clinical disease elsewhere in the body.
  • There are no reported cases of monoclonal gammopathy of undetermined significance progressing to AL-Amyloid presenting as lower gastrointestinal hemorrhage.
  • We report a case of a patient initially diagnosed with monoclonal gammopathy of undetermined significance who progressed to AL-Amyloid over the course of 1 year.
  • The diagnosis was made by biopsy of a sigmoid plaque demonstrating necrotic material on histopathology.
  • We conclude that early endoscopic examination and biopsy of the surrounding intestinal tissue is indicated when patients with monoclonal gammopathy of undetermined significance present with gastrointestinal hemorrhage to evaluate for the progression to AL-Amyloidosis.
  • Treatment to prevent recurrent hemorrhage and further progression of the disease should be considered.
  • [MeSH-major] Amyloidosis / complications. Amyloidosis / diagnosis. Gastrointestinal Hemorrhage / etiology
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Male


92. Kyle RA, Kumar S: The significance of monoclonal gammopathy of undetermined significance. Haematologica; 2009 Dec;94(12):1641-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The significance of monoclonal gammopathy of undetermined significance.
  • [MeSH-major] Monoclonal Gammopathy of Undetermined Significance / diagnosis. Monoclonal Gammopathy of Undetermined Significance / mortality

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 2001 Feb;112(2):353-7 [11167828.001]
  • [Cites] Haematologica. 2009 Dec;94(12):1714-20 [19608666.001]
  • [Cites] N Engl J Med. 2002 Feb 21;346(8):564-9 [11856795.001]
  • [Cites] Mayo Clin Proc. 2003 Jan;78(1):21-33 [12528874.001]
  • [Cites] Br J Haematol. 2003 Jun;121(5):749-57 [12780789.001]
  • [Cites] Immunol Rev. 2003 Aug;194:112-39 [12846812.001]
  • [Cites] Mayo Clin Proc. 2004 Jul;79(7):859-66 [15244381.001]
  • [Cites] Am J Med. 1978 May;64(5):814-26 [645746.001]
  • [Cites] J Lab Clin Med. 1990 Dec;116(6):785-9 [2246554.001]
  • [Cites] Br J Haematol. 1995 Sep;91(1):121-5 [7577618.001]
  • [Cites] Am J Med. 1998 May;104(5):439-44 [9626026.001]
  • [Cites] N Engl J Med. 2006 Mar 30;354(13):1362-9 [16571879.001]
  • [Cites] Mayo Clin Proc. 2007 Dec;82(12):1468-73 [18053453.001]
  • [Cites] Mayo Clin Proc. 2007 Dec;82(12):1474-9 [18053454.001]
  • [Cites] Best Pract Res Clin Haematol. 2007 Dec;20(4):637-64 [18070711.001]
  • [Cites] Leukemia. 2008 Feb;22(2):231-9 [17972944.001]
  • [Cites] Br J Haematol. 2009 Jan;144(2):176-84 [19036113.001]
  • [Cites] Blood. 2009 May 28;113(22):5412-7 [19179464.001]
  • [Cites] Blood. 2009 May 28;113(22):5418-22 [19234139.001]
  • [Cites] Blood. 2009 Jun 18;113(25):6386-91 [19387005.001]
  • [Cites] Blood. 2009 Jul 23;114(4):785-90 [19179466.001]
  • [CommentOn] Haematologica. 2009 Dec;94(12):1714-20 [19608666.001]
  • (PMID = 19996115.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comment; Editorial; Research Support, N.I.H., Extramural
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2791927
  •  go-up   go-down


93. Kyle RA, Rajkumar SV, Therneau TM, Larson DR, Plevak MF, Melton LJ 3rd: Prognostic factors and predictors of outcome of immunoglobulin M monoclonal gammopathy of undetermined significance. Clin Lymphoma; 2005 Mar;5(4):257-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors and predictors of outcome of immunoglobulin M monoclonal gammopathy of undetermined significance.
  • Monoclonal gammopathy of undetermined significance (MGUS) of the immunoglobulin M (IgM) class was diagnosed at our institution in 213 patients who resided in the 11 counties of southeastern Minnesota from 1960 to 1994.
  • The median age at diagnosis was 74 years and the median concentration of serum M-protein was 1.2 g/dL.
  • During follow-up, non-Hodgkin's lymphoma (n = 17), Waldenstrom's macroglobulinemia (n = 6), primary amyloidosis (n = 3), and chronic lymphocytic leukemia (n = 3) developed in 29 patients (14%).
  • Multivariate analysis revealed that only the concentration of serum M-protein at diagnosis and the serum albumin value were independent predictors of progression.
  • It was concluded that the patients with IgM MGUS should be followed indefinitely.
  • [MeSH-minor] Adult. Age of Onset. Aged. Aged, 80 and over. Disease Progression. Female. Follow-Up Studies. Humans. Lymphoma / pathology. Male. Middle Aged. Multivariate Analysis. Prognosis. Risk Factors. Survival Analysis

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15794860.001).
  • [ISSN] 1526-9655
  • [Journal-full-title] Clinical lymphoma
  • [ISO-abbreviation] Clin Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 62242
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin M
  •  go-up   go-down


94. Markotić A, Skerk V, Cvetko Krajinović L, Beus A: Is the clinical picture of Schnitzler syndrome always Schnitzler syndrome? Clin Exp Rheumatol; 2009 May-Jun;27(3):507-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Both patients had two major (monoclonal gammopathy and chronic urticaria) and almost all minor symptoms (e.g. arthralgia, bone pain, fever, etc.) of Schnitzler syndrome.
  • Our statement is that, besides clinical symptoms and signs, additional immune parameters should be tested before diagnosis of Schnitzler syndrome is established.
  • [MeSH-major] Schnitzler Syndrome / diagnosis. Schnitzler Syndrome / immunology
  • [MeSH-minor] CD4-Positive T-Lymphocytes / pathology. CD40 Ligand / blood. Diagnosis, Differential. Female. Granulocyte Colony-Stimulating Factor / blood. Humans. Interleukin-17 / blood. Interleukin-1beta / blood. Killer Cells, Natural / pathology. Male. Middle Aged. Urticaria / diagnosis. Urticaria / immunology. Urticaria / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19604447.001).
  • [ISSN] 0392-856X
  • [Journal-full-title] Clinical and experimental rheumatology
  • [ISO-abbreviation] Clin. Exp. Rheumatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / IL25 protein, human; 0 / Interleukin-17; 0 / Interleukin-1beta; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 147205-72-9 / CD40 Ligand
  •  go-up   go-down


95. Hamidah NH, Azma RZ, Ezalia E, Das S, Umar NA, Swaminathan M, Mohamed Z, Abdul Wahid SF: Non-secretory multiple myeloma with diagnostic challenges. Clin Ter; 2010;161(5):445-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-secretory multiple myeloma with diagnostic challenges.
  • Non-secretory multiple myeloma (NSMM) is a rare variant of the classic form of multiple myeloma (MM).
  • In NSMM, no monoclonal gammopathy can be detected in serum or urine by conventional techniques, making the diagnosis more difficult.
  • Skeletal X-rays showed diffuse osteolytic lesions with multiple pathological fractures but there was no monoclonal gammopathy in the serum or urine.
  • The biopsy of the lytic lesion on the upper part of the femur showed infiltration by abnormal plasma cells.
  • A diagnosis of NSMM was made and he was treated with chemotherapy.
  • [MeSH-major] Multiple Myeloma / diagnosis

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20949241.001).
  • [ISSN] 1972-6007
  • [Journal-full-title] La Clinica terapeutica
  • [ISO-abbreviation] Clin Ter
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


96. Soubrier M: [POEMS syndrome]. Presse Med; 2007 Nov;36(11 Pt 2):1676-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The POEMS syndrome combines a constant polyneuropathy (P), organomegaly (O), endocrinopathy (E), monoclonal gammopathy (M) (or other plasma cell disorder) and skin changes (S).
  • Consistent plasma cell disorders include a monoclonal component, often in small quantities with a lambda light chain isotype, and plasmacytoma, often solitary lesions.
  • Treatment depends on specific characteristics of the disease and the patient (radiation therapy for plasmocytoma, autologous bone marrow transplantation in young subjects, corticosteroid therapy or chemotherapy in the elderly).

  • Genetic Alliance. consumer health - POEMS syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17629447.001).
  • [ISSN] 0755-4982
  • [Journal-full-title] Presse medicale (Paris, France : 1983)
  • [ISO-abbreviation] Presse Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 28
  •  go-up   go-down


97. Kimura S, Iwatsuka R, Aoki T, Odawara J, Asada N, Yamakura M, Takeuchi M, Matsue K: [Primary amyloidosis associated with IgD-lambda M-proteinemia]. Rinsho Ketsueki; 2007 Dec;48(12):1555-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe here a case of primary AL amyloidosis associated with IgD monoclonal gammopathy of undetermined significance.
  • Although serum electrophoresis revealed IgDlambda monoclonal protein, the bone marrow did not showed plasma cell proliferation.
  • A diagnosis of primary AL amyloidosis associated with IgD monoclonal gammopathy was made.
  • To our knowledge, this is the first report of primary AL amyloidosis associated with IgD monoclonal gammopathy with undetermined significance.

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18203516.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Immunoglobulin D; 0 / Immunoglobulin lambda-Chains; 0 / Immunoglobulin mu-Chains
  •  go-up   go-down


98. Fend F: [Molecular pathology of plasma cell neoplasms]. Pathologe; 2010 Oct;31 Suppl 2:188-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Molecular pathology of plasma cell neoplasms].
  • Plasma cell myeloma (PCM) and related immunosecretory disorders are a group of B-cell proliferations with a wide clinical and prognostic spectrum, characterized by the production of monoclonal immunoglobulin by immortalized plasma cells.
  • There is good evidence to support a multistep transformation process in plasma cell neoplasms, which corresponds to clinically discernible disease stages.
  • Monoclonal gammopathy of unknown significance is a common asymptomatic precursor lesion for PCM which carries an approximately 1% annual risk for progression.
  • Terminal disease stages are characterized by increasing genetic complexity and independence from bone marrow stromal cells and show a rapidly increasing tumour load with severe clinical symptoms.
  • Modern diagnostics of plasma cell neoplasms require inclusion of clinical, morphological, immunophenotypical and cytogenetic features to allow for individual risk assessment and therapy planning.
  • [MeSH-major] Neoplasms, Plasma Cell / genetics. Neoplasms, Plasma Cell / pathology
  • [MeSH-minor] Body Burden. Bone Marrow / pathology. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / pathology. DNA Mutational Analysis. Diagnosis, Differential. Disease Progression. Gene Expression Regulation, Neoplastic / genetics. Humans. In Situ Hybridization, Fluorescence. Neoplasm Staging. Paraproteinemias / genetics. Paraproteinemias / pathology. Plasmacytoma / genetics. Plasmacytoma / pathology. Risk Factors. Translocation, Genetic / genetics

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2004 Jun;28(6):736-47 [15166665.001]
  • [Cites] Br J Haematol. 2003 Jun;121(5):749-57 [12780789.001]
  • [Cites] Cancer Res. 2004 Feb 15;64(4):1546-58 [14989251.001]
  • [Cites] Blood. 1998 Nov 1;92(9):3025-34 [9787135.001]
  • [Cites] J Pathol. 2005 Jan;205(1):92-101 [15586381.001]
  • [Cites] Blood. 2004 Aug 15;104(4):1120-6 [15090460.001]
  • [Cites] Leukemia. 2009 Dec;23(12):2210-21 [19798094.001]
  • [Cites] Am J Clin Pathol. 2007 Aug;128(2):339-44 [17638671.001]
  • [Cites] Oncogene. 2001 Sep 10;20(40):5611-22 [11607813.001]
  • [Cites] Blood. 2009 May 28;113(22):5418-22 [19234139.001]
  • [Cites] Blood. 2005 Jul 1;106(1):296-303 [15755896.001]
  • [Cites] Am J Pathol. 2003 May;162(5):1449-61 [12707028.001]
  • [Cites] Blood. 2006 Sep 15;108(6):2020-8 [16728703.001]
  • [Cites] Blood. 1995 Nov 15;86(10):3915-21 [7579361.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):13931-6 [8943038.001]
  • [Cites] Blood. 2004 Aug 1;104(3):607-18 [15090448.001]
  • [Cites] Leukemia. 2004 Nov;18(11):1883-90 [15356648.001]
  • [Cites] Haematologica. 2008 Apr;93(4):623-6 [18326524.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4995-5001 [17303695.001]
  • [Cites] Mod Pathol. 2010 Jul;23(7):991-9 [20348882.001]
  • [Cites] Blood. 1998 Jan 1;91(1):3-21 [9414264.001]
  • [Cites] Blood. 2001 Nov 15;98(10):3082-6 [11698294.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6333-8 [16155016.001]
  • [Cites] Curr Top Microbiol Immunol. 1997;224:283-7 [9308253.001]
  • [Cites] Blood. 1999 Feb 15;93(4):1330-7 [9949176.001]
  • [Cites] Leukemia. 2004 Nov;18(11):1879-82 [15385925.001]
  • (PMID = 20852863.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  •  go-up   go-down


99. Golombick T, Diamond T: Prevalence of monoclonal gammopathy of undetermined significance/myeloma in patients with acute osteoporotic vertebral fractures. Acta Haematol; 2008;120(2):87-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence of monoclonal gammopathy of undetermined significance/myeloma in patients with acute osteoporotic vertebral fractures.


100. Dispenzieri A, Gertz MA, Lacy MQ, Geyer SM, Greipp PR, Rajkumar SV, Kimlinger T, Lust JA, Fonseca R, Allred J, Witzig TE: A phase II trial of imatinib in patients with refractory/relapsed myeloma. Leuk Lymphoma; 2006 Jan;47(1):39-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • As pre-clinical data, 126 patients with plasma cell disorders and 19 controls were evaluated for c-kit expression.
  • Of the 145 studied before the trial, c-kit expression was present on the bone marrow plasma cells of control (11%), AL amyloid (53%), MGUS (47%), SMM (67%) and MM (42%) patients.
  • Patients ended treatment due to progressive disease (18 patients), death (3) and other (2).
  • [MeSH-minor] Aged. Aged, 80 and over. Benzamides. Cell Line, Tumor. Cell Proliferation / drug effects. Disease Progression. Disease-Free Survival. Female. Gene Expression Regulation, Leukemic / drug effects. Gene Expression Regulation, Leukemic / genetics. Humans. Imatinib Mesylate. Male. Middle Aged. Proto-Oncogene Proteins c-kit / drug effects. Proto-Oncogene Proteins c-kit / genetics. Receptors, Platelet-Derived Growth Factor / genetics. Recurrence. Retrospective Studies. Survival Rate. Time Factors. Treatment Failure

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16321825.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptors, Platelet-Derived Growth Factor
  •  go-up   go-down






Advertisement